A multifaceted GABA<sub>A</sub> receptor modulator: Functional properties and mechanism of action of the sedative-hypnotic and recreational drug methaqualone (Quaalude®)


Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen OE, Denmark (H.H., L.B, K.H.-J. and A.A.J).


Methaqualone (Quaalude®) is a multifaceted GABA\(_A\)R modulator

Corresponding Author: Anders A. Jensen, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Fax: +45 35336041, Phone: +45 39179650, email: aaj@sund.ku.dk

Number of Pages: 64 (excl. figures)
Number of Figures: 11
Number of Tables: 3
Number of References: 95
Number of Words - Abstract: 250
Number of Words - Introduction: 655
Number of Words - Discussion: 1543

**ABBREVIATIONS:**

GABA, \(\gamma\)-aminobutyric acid; GABA\(_A\)Rs, \(\gamma\)-aminobutyric acid type A receptors; MEA, microelectrode array; MEST, maximal electroshock seizures threshold; NAM, negative allosteric modulator; PAM, positive allosteric modulator; PDSP, Psychoactive Drug Screening Program; TEVC, two-electrode voltage clamp; WT, wild type.
ABSTRACT

In the present study we have elucidated the functional characteristics and mechanism of action of methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone, Quaalude®), an infamous sedative-hypnotic and recreational drug from the 1960-70s. Methaqualone was demonstrated to be a positive allosteric modulator (PAM) at human α1,2,3,5β2,3γ2S GABA_A receptors (GABA_ARs) expressed in Xenopus oocytes, whereas it displayed highly diverse functionalities at the α4,6β1,2,3δ GABA_AR subtypes, ranging from inactivity (α4β1δ), through negative (α6β1δ) or positive allosteric modulation (α4β2δ, α6β2,3δ), to superagonism (α4β3δ). Methaqualone did not interact with the benzodiazepine, barbiturate or neurosteroid binding sites in the GABA_AR. Instead, the compound is proposed to act through the transmembrane β(+)/α(−) subunit interface of the receptor, possibly targeting a site overlapping with that of the general anesthetic etomidate. The negligible activities displayed by methaqualone at numerous neurotransmitter receptors and transporters in an elaborate screening for additional putative CNS targets suggest that it is a selective GABA_AR modulator. The mode of action of methaqualone was further investigated in multichannel recordings from primary frontal cortex networks, where the overall activity changes induced by the compound at 1-100 µM concentrations were very similar to those mediated by other CNS depressants. Finally, the free methaqualone concentrations in mouse brain arising from doses producing significant in vivo effects in assays for locomotion and anticonvulsant activity were found to correlate fairly well with its potencies as a modulator at the recombinant GABA_ARs. Hence, we propose that the multifaceted functional properties exhibited by methaqualone at GABA_ARs give rise to its effects as a therapeutic and recreational drug.
INTRODUCTION

Methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone) has a colorful history as a therapeutic and recreational drug. Methaqualone was marketed in the early 1960s as a safe non-barbiturate hypnotic with a wide safety margin and low abuse potential under trade names like Quaalude®, Parest®, Somnafac®, Revonal® and as the combination drug Mandrax® (with the anti-histamine diphenhydramine). In the following years, methaqualone became one of the best-selling sedative-hypnotic drugs worldwide, with several structural analogs following in its trail (collectively referred to as “quaaludes”) (Carroll and Gallo, 1985; Gass, 2008). However, clinical use of the drug soon revealed that besides giving rise to serious adverse effects, it was highly addictive and induced tolerance and cross-tolerance with other hypnotics. Moreover, concomitantly with its therapeutic use methaqualone became highly popular as a recreational drug, where it often was consumed in combination with alcohol (known as “luding out”) (Falco, 1976; Gass, 2008; Herzberg, 2011; McCarthy et al., 2005). These problems led to the implementation of tighter regulation of the drug, and by the mid-1980s it had been withdrawn from most markets (Carroll and Gallo, 1985; Gass, 2008). Nevertheless, recreational use of illegally produced methaqualone still constitutes a substantial health problem in some parts of the world (McCarthy et al., 2005; Parry et al., 2004).

The overall clinical properties of methaqualone are very characteristic for a sedative-hypnotic drug, however, some of its in vivo effects differ from those induced by classical CNS depressants. Methaqualone reportedly mediates a rapid induction of a more natural deep sleep resulting in less severe dizziness/dullness and headaches in insomnia patients than benzodiazepines and barbiturates (Barcelo, 1961; Ionescu-Pioggia et al., 1988). Furthermore, unlike most sedatives methaqualone is also quite efficacious as an antispasmodic (Gass, 2008). Finally, the euphoria and aphrodisiac properties constituting some of the major psychological
effects evoked by methaqualone in its recreational use are effects not typically associated with CNS depressants (Barceloux, 2012; Falco, 1976; Gass, 2008; Ionescu-Pioggia et al., 1988). Although the electroencephalographic effects induced by methaqualone in rodent and human brain largely resemble those produced by barbiturates and other CNS depressants, the fact that some qualitative differences have been observed between these drugs in these recordings seems to support the clinical observations (Pfeiffer et al., 1968; Saxena et al., 1977).

While the therapeutic and psychotropic effects of methaqualone arguably have been comprehensively documented, the molecular basis for these effects has never been investigated. Based on the overall similarities between its behavioral effects and those induced by barbiturates and benzodiazepines, methaqualone has been assumed to act through the γ-aminobutyric acid type A receptors (GABA\(_A\)Rs) (Carroll and Gallo, 1985; Gass, 2008). This family of ligand-gated anion channels comprises a plethora of receptors assembled from 19 subunits (\(\alpha_{1-6}\), \(\beta_{1-3}\), \(\gamma_{1-3}\), \(\delta\), \(\varepsilon\), \(\theta\), \(\pi\) and \(\rho_{1-3}\)), and the complexity of GABAergic neurotransmission largely arises from differential regional and cellular expression of these subtypes (Brickley and Mody, 2012; Olsen and Sieghart, 2008; Whiting, 2003). The pentameric GABA\(_A\)R complex is typically comprised of two \(\alpha\) subunits, two \(\beta\) subunits and a \(\gamma\) or \(\delta\) subunit, and the receptor comprises numerous allosteric sites through which GABA-evoked signaling can be modulated by various drugs, including barbiturates, benzodiazepines, neurosteroids and anesthetics (Sieghart, 2015). In contrast to the well-established role of GABA\(_A\)Rs as the principal mediators of the effects of these drugs, however, the link between methaqualone and GABAergic neurotransmission is founded on strikingly sparse and largely inconclusive experimental data (Hicks et al., 1990; Müller et al., 1978; Naik et al., 1978).
In the present study methaqualone has been subjected to an elaborate functional characterization at human GABA\(_A\)R subtypes expressed in *Xenopus* oocytes, and its molecular mechanism of action at the receptors has been delineated. Furthermore, the functionality of methaqualone at native GABA\(_A\)Rs has been elucidated by multiparametric analysis of its electrophysiological effects at cortical neuron network activity. Finally, the correlation between the functional properties of methaqualone at GABA\(_A\)Rs *in vitro* and its *in vivo* efficacy in mice models for locomotion and anticonvulsant activity has been investigated.
MATERIALS AND METHODS

**Materials.** GABA, diazepam, ZnCl$_2$ and chemicals for buffers were obtained from Sigma-Aldrich (St. Louis, MO). Methaqualone (Figure 1A) was synthesized by the MedChem Department at H. Lundbeck A/S. Pentobarbital and allopregnanolone were purchased from May and Baker (Dagenham, UK) and Merck Chemicals (Nottingham, UK), respectively. Flumazenil and etomidate were purchased from Abcam Biochemicals (Cambridge, UK), and DS2 was obtained from Tocris Cookson (Bristol, UK). Defolliculated stage V-VI oocytes harvested from female *Xenopus laevis* frogs (using MS222 as anesthetic) were obtained from Lohmann Research Equipment (Castrop-Rauxel, Germany).

**Molecular Biology.** The subcloning of human $\alpha_1$-$\alpha_6$, $\beta_1$, $\beta_2$, $\delta$ and $\gamma_{2S}$ cDNAs into pcDNA3.1 has been described previously (Jensen et al., 2010), and the human $\beta_3$ cDNA used in this study was in pGEMHE. Point mutations were introduced into cDNAs using the QuikChange mutagenesis kit (Stratagene, Santa Clara, CA) and oligonucleotides from TAG Copenhagen A/S (Copenhagen, Denmark). The integrity and the absence of unwanted mutations in all cDNAs created by PCR was verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany).

*Xenopus laevis* oocytes and TEVC recordings. The functional characterization of methaqualone at wild type (WT) and mutant GABA$_A$Rs expressed in *Xenopus* oocytes was performed essentially as previously described (Hoestgaard-Jensen et al., 2013). The GABA$_A$R cDNAs were linearized and applied as templates for *in vitro* cRNA synthesis using the T7 mMESSAGE mMACHINE High Yield Capped RNA Transcription Kit (Life Technologies Corporation, Carlsbad, CA, USA). 9 or 18 nL cRNA encoding for $\alpha_1$$\beta_2$ ($\alpha_1$:$\beta_2$ ratio: 0.06:0.06 µg/µL) and $\alpha_{1,2,3,5}$$\beta_2$$\gamma_{2S}$ GABA$_A$Rs ($\alpha$:$\beta$: $\gamma_{2S}$ ratio: 0.01:0.01:0.01 µg/µL), or 46 nL cRNA
encoding for \(\alpha_6\beta_2\) (\(\alpha_6:\beta_2\) ratio: 1:0.1 \(\mu\text{g}/\mu\text{L}\)) and \(\alpha_{4,6}\beta_{1,2,3}\delta\) GABA\(_A\)Rs (\(\alpha:\beta:\delta\) ratio: 1:0:1 \(\mu\text{g}/\mu\text{L}\)) were injected into oocytes, which subsequently were incubated at 18°C in modified Barth’s solution [88 mM NaCl, 1 mM KCl, 15 mM HEPES (pH 7.5), 2.4 mM NaHCO\(_3\), 0.41 mM CaCl\(_2\), 0.82 mM MgSO\(_4\), 0.3 mM Ca(NO\(_3\))\(_2\), 100 U/ml penicillin and 100 \(\mu\text{g}/\text{ml}\) streptomycin]. Whole-cell currents in the \(\alpha_1\beta_2/\alpha_{1,2,3,5}\beta_{2,3}\gamma_{2S}\)- and \(\alpha_6\beta_2/\alpha_{4,6}\beta_{1,2,3}\delta\)-expressing oocytes were measured 1-4 and 3-6 days after cRNA injection, respectively. In the two-electrode voltage clamp (TEVC) recordings, the oocytes were placed in a recording chamber continuously perfused with a saline solution [115 mM NaCl, 2.5 mM KCl, 10 mM HEPES (pH 7.5), 1.8 mM CaCl\(_2\), 0.1 mM MgCl\(_2\)], and the test compounds were applied in the perfusate. Both voltage and current electrodes were agar-plugged with 3 M KCl and displayed resistances between 0.5-2.0 MΩ. Oocytes were voltage-clamped at -40 mV to -80 mV (depending on the current size) using an Oocyte Clamp OC-725C amplifier (Warner Instruments, Hamden, CT). The incorporation of the \(\gamma_{2S}\) subunit into the GABA\(_A\)Rs assembled at the cell surface of \(\alpha_{1,2,3,5}\beta_{2,3}\gamma_{2S}\)-expressing oocytes was confirmed on a routinely basis with 100 \(\mu\text{M}\) ZnCl\(_2\) (Karim et al., 2013), and the presence of \(\delta\) in cell surface-expressed receptors in \(\alpha_{4,6}\beta_{1,2,3}\delta\)-injected oocytes was verified using the \(\delta\)-GABA\(_A\)R selective PAM DS2 (1 \(\mu\text{M}\)) and 1 \(\mu\text{M}\) ZnCl\(_2\) (Karim et al., 2012; Storustovu and Ebert, 2006; Wafford et al., 2009).

In the experiments where the functional properties of GABA or methaqualone as agonists at the various receptors were characterized, 10 \(\mu\text{M}\) GABA was applied to the perfusate until the peak of the response was observed, usually within 30 s. When two consecutive applications of GABA had elicited responses of comparable sizes (± 5%), various concentrations of GABA or methaqualone were applied. In the experiments where the functional properties of various allosteric modulators were characterized, the GABA concentration that was to be used (GABA
EC\textsubscript{10} or GABA EC\textsubscript{60-70} was determined on the day of the experiment by measurements on two oocytes expressing the specific receptor. Subsequently, when two consecutive applications of GABA EC\textsubscript{10} or GABA EC\textsubscript{60-70} were applied to the perfusate and observed to elicit currents of comparable sizes (± 5%), the functional characteristics of the allosteric modulators at the GABA\textsubscript{A}R were determined by pre-application of the modulator to the perfusate 30 s prior to the co-application of the modulator and GABA. In all recordings a 2.5 min wash was executed between all applications to prevent receptor desensitization. At the end of each recording on an oocyte, a GABA concentration evoking the maximum response through the specific receptor was applied in the perfusate. Experiments were performed at room temperature and each data point represents the mean ± S.E.M. value of recordings performed on at least three oocytes from at least two different batches of oocytes.

The recorded baseline-to-peak current amplitudes were analysed using Clampfit 10.1 (Axon Instruments, Union City, CA, USA), and data for the test compounds was normalized to the maximal response elicited by GABA on each oocyte. Data analysis and statistical analysis was performed using Prism GraphPad, version 6.0a (GraphPad Software, Inc. La Jolla, CA, USA). Concentration-response and concentration-inhibition curves were fitted by nonlinear regression using the equation for sigmoidal dosage-response with variable slope. Comparison of best fitting equation (monophasic vs. biphasic) was carried out using the extra sum-of-squares F-test, and the null hypothesis was rejected at P < 0.05. When a biphasic fit was the statistically better model, data were fitted to the equation for a biphasic dose-response curve using nonlinear regression. Unless otherwise stated in the figure legends, statistical analysis was performed using ordinary one-way ANOVA. The null hypothesis was rejected at P < 0.05, and the differences between the means were analysed by Dunnett’ s multiple comparisons test, with a single pooled variance.
**In silico study.** The modeling study was performed using the software package MOE 2013.08 (Molecular Operating Environment, Chemical Computing Group) using the built-in mmff94x force field and the GB/SA continuum solvation model. Etomidate, loreclezole and methaqualone were submitted to a stochastic conformational search (standard setup) to enumerate low-energy conformations. Structurally collapsed conformations were discarded and superimposition of selected low-energy conformations (up to $\Delta \Delta G=3$ kcal/mol) was done using the built-in function by fitting the carbonyl groups of etomidate and methaqualone and the vinylogous chlorine of loreclezole.

**Screening of methaqualone at various CNS targets.** The *in vitro* binding profiling of methaqualone in competition radiobinding assays at a total of 53 CNS targets were performed by the National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP). Detailed information about the binding assay protocols are given at http://pdsp.med.unc.edu/pdspw/binding.php. In brief, the majority of the binding assays were performed to homogenates of mammalian cell lines transiently or stable expressing the different targets, with a few assays being performed using homogenized rat brain tissue. Methaqualone was tested in an assay concentration of 30 µM, and an assay concentration of the radioligand near or at the $K_D$ value for the specific target was used. The functional characterization of methaqualone at $\text{GABA}_B$ receptors and at the $\alpha_4\beta_2$ nicotinic acetylcholine receptor in fluorescence-based $\text{Ca}^{2+}$/Fluo-4 or membrane potential assays and at the human four $\text{GABA}$ transporters in a conventional $[^3\text{H}]\text{GABA}$ uptake assay was performed essentially as described previously (Hoestgaard-Jensen et al., 2014; Trattnig et al., 2012).
Functional phenotypic characterization of methaqualone at neuronal cell cultures. The effects of methaqualone at cortical network activity in vitro were characterized essentially as previously described for the opioid ligand LP1 (Parenti et al., 2013).

Primary cell cultures. Frontal cortex tissue was harvested from embryonic day 15/16 chr:NMRI mice (Charles River). The mice were sacrificed by cervical dislocation according to the German Animal Protection Act §4. Tissue was dissociated by enzymatic digestion (133.3 Kunitz units/ml DNase, 10 Units/ml papain) and mechanical trituration, counted, vitality controlled, and plated in DMEM containing 5% fetal bovine serum and 5% horse serum on poly-D-lysine- and laminin-coated microelectrode array (MEA) neurochips with 64 passive electrodes (Center for Network NeuroScience, University of North Texas, Denton, TX). Cultures on the MEA chips were incubated at 37 °C in a 10% CO₂ atmosphere until ready for use, usually four weeks after seeding. Culture media were replenished two times a week with DMEM containing 10% horse serum. The developing co-cultures were treated with the mitosis inhibitor 5-fluoro-2'-deoxyuridine (25 µM) and uridine (63 µM) for 48 h on day 5 after seeding to prevent further glial proliferation. After 4 weeks in culture, the activity pattern stabilizes and is composed of one coordinated main burst pattern with several coordinated sub-patterns (Gramowski et al., 2006a; Gramowski et al., 2004; Gramowski et al., 2006b). In this study cultures between 28 and 35 days in vitro were used.

Multichannel recordings and data analysis. Extracellular recordings were performed using a computer-controlled 64-channel MEA workstation acquisition system (Plexon, Inc., Dallas, TX), where temperature control of 37°C and stable pH of 7.4 (10% CO₂) enabled stable recording and cumulative concentration-response determinations for periods longer than 10 h (Parenti et al., 2013). The neuronal networks were acutely treated with a series of accumulating increasing concentrations of the test compound (maximum assay concentration of DMSO: 0.1%). For each
of the applied test compound concentrations a stable activity phase of the last 30 min was analysed, and real time unit separation and spike identification were performed in real time as previously described (Parenti et al., 2013). Action potentials, termed “spikes”, were recorded as spike trains, which in cortical neurons are clustered in bursts (Gramowski et al., 2006a), and these were quantitatively described via direct spike train analysis using the programs NeuroEXplorer (Plexon Inc., Dallas, TX) and the proprietary tool NPWaveX. Bursts definition and high content analysis of the network activity patterns provided a multiparametric description characterizing the activity changes in four defined categories: overall activity, burst structure, oscillatory behaviour and synchronicity (see (Parenti et al., 2013) for more information). The parameters for each experiment and each experimental treatment were normalized to the corresponding values of the native reference activity. From each network 21-158 separate neurons were simultaneously recorded.

Pattern recognition and classification. The characteristics of the effects displayed by methaqualone on the activity of cortical networks were elucidated further by analysis of the electrophysiological data using methods of pattern recognition and cross validation as previously described (Parenti et al., 2013). 204 spike train features were calculated using NPWaveX (NeuroProof GmbH, Rostock, Germany). Activity changes within these 204 features over the tested concentration range generate a functional, phenotypic profile for a compound. Methaqualone data were subsequently classified using pattern recognition (software package PatternExpert, NeuroProof GmbH, Rostock, Germany) by comparison to the phenotypic profiles of 69 reference compounds from the NeuroProof database. An artificial neuronal network was trained with the datasets from the reference compounds to establish a classifier (multi-layer feed forward network and back propagation algorithm without hidden units). It uses a multi-layer feed forward perceptron and a resilient-propagation learning algorithm that uses as many input nodes
as features and one output node for each class that has to be classified. Relatively high variation of our data justifies non-usage of hidden layers. The thereby obtained cross validation delivers a ranking that reflects the functional similarity between methaqualone datasets and reference compound. This analysis was repeated 10 times. The values reflect “% of methaqualone datasets classified as a phenotypic reference profile” named similarity score. High values reflect high functional phenotypic similarity between reference compound profiles and methaqualone.

**Animal studies.** Animals. Male NMRI mice (20-24 g at the time of testing) from Charles River (Germany) were housed under controlled conditions (12 h of light starting at 0600 hours, 20 ± 2 °C, 30–70 % humidity) in Macrolon (type III) cages, with standard sawdust bedding and environmental enrichment (plastic house and wooden chew blocks), and food and water available ad libitum. The experiments were carried out in accordance with the Danish legislation regulating animal experiments; Law and Order on Animal experiments; Act No. 474 of 15/05/2014 and Order No. 88 of 30/01/2013, and with the specific license for this experiment issued by the National Authority.

**Maximal electroshock seizures threshold and beam walk assays.** Methaqualone was tested 60 min and diazepam 30 min after a subcutaneous dose in the beam walk assay, which is a sensitive measure of sedation/ataxia side-effects. Briefly, mice walk across a wooden beam, 8 mm in diameter and 60 cm long to a goal box at the far end. The number of foot slips and number of falls from the beam are the scored (Stanley et al., 2005). The same mouse is first tested in beam walking, and then the convulsion threshold is determined by the maximal electroshock seizures threshold (MEST) to tonic hind limb extension by electrical stimulation via corneal electrodes using the using the ‘up and down’ method of shock titration (Kimball et al., 1957; Löscher and Schmidt, 1988). Electrical stimulation was delivered by electrical stimulator (Ellegaard Systems, Faaborg, Denmark) as constant current for 0.4 sec at 50 Hz starting at 14 mA and the stimulation...
intensity was lowered or raised by 2 mA steps if preceding mouse did or did not show hind limb extension, respectively. In the same mouse, plasma and brain samples were taken to directly link efficacy to exposure.

**Plasma and brain exposure analysis.** Mice plasma and brain samples from the MEST study were analysed for methaqualone using Ultra Performance LC chromatography followed by MS/MS detection. Brain homogenate samples were prepared by homogenizing the brain 1:4 (v/v) with water:2-propanol:DMSO (50:30:20 v/v/v) followed by centrifugation and collection of the supernatant. Sample preparation was performed by protein precipitation with acetonitrile followed by centrifugation and addition of 0.1% ammonium hydroxide. The mobile phase consisted of water/acetonitrile with ammonium hydroxide pumped through an analytical column (Acquity UPLC BEH Phenyl column 1.8 µm, 2.1 x 30 mm, Waters, MA). Detection was performed using a Sciex-API 4000 MS (Applied Biosystems, The Netherlands) using electrospray with positive ionization mode with a parent>daughter molecular mass of 251.1>91.1 amu. The lower limit of quantification was 1 ng/mL in plasma and 5 ng/g in brain (peak S/N> 6). The free fraction of methaqualone was determined in vitro using standard equilibrium dialysis methodology with freshly isolated mouse brain homogenate or plasma (Redrobe et al., 2012). Equilibrium dialysis was performed by incubating at 37°C for 5 h in triplicates.
RESULTS

Functional characterization of methaqualone at human GABA_A Rs expressed in Xenopus oocytes. The functional properties of methaqualone were characterized at 13 human GABA_A R subtypes expressed in Xenopus oocytes by TEVC electrophysiology. While GABA displayed monophasic concentration-response relationships at the majority of the receptors, its concentration-response curves at the α_4β_3δ GABA_A R were distinctly biphasic, and recordings from α_4β_1δ-oocytes resulted in both monophasic and biphasic concentration-response curves (Table 1). In agreement with previous reports (Hoestgaard-Jensen et al., 2014; Jensen et al., 2013; Karim et al., 2012), the receptors formed in α_4β_1δ- and α_4β_3δ-expressing oocytes also exhibited pronounced levels of constitutive activity (assessed by application of 10 µM picrotoxin, data not shown). All in all, these basic functional properties of the receptors were in good agreement with those obtained in previous studies (Hoestgaard-Jensen et al., 2014; Hoestgaard-Jensen et al., 2013; Karim et al., 2012; Karim et al., 2013; Mortensen et al., 2011).

In the initial round of characterization, the functional properties of methaqualone were determined at α_1β_2γ_2S, α_2β_2γ_2S, α_3β_2γ_2S, α_4β_2δ, α_5β_2δ_ and α_6β_2δ GABA_A Rs (Figure 1). This selection of receptors not only represents the full spectrum of molecular diversity in terms of α-subunits but also comprises six major physiological GABA_A R subtypes (Belelli et al., 2009; Brickley and Mody, 2012; Olsen and Sieghart, 2008). Methaqualone displayed negligible agonism at the α_1,2,3,5β_2γ_2S receptors (R_{max} values of 1-4 % of GABA R_{max}), whereas it was more efficacious as an agonist at α_4β_2δ (R_{max} ± S.E.M: 5.5 ± 1.6 %, N = 5) and α_6β_2δ (R_{max} ± S.E.M: 13 ± 1.6 %, N = 8). In addition to its small intrinsic agonist activity, methaqualone was a positive allosteric modulator (PAM) exhibiting mid-micromolar EC_{50} values at all six receptors when co-applied with GABA EC_{10} (Figure 1B, Table 1). The currents evoked by GABA EC_{10} in α_1β_2γ_2S-,
\(\alpha_2\beta_2\gamma_2S\), \(\alpha_5\beta_2\gamma_2S\)- and \(\alpha_5\beta_2\gamma_2S\)-oocytes were potentiated 6-8 fold by maximal potentiating concentrations of methaqualone. The compound was an even more efficacious PAM at the \(\alpha_4\beta_2\delta\) and \(\alpha_6\beta_2\delta\) GABA\(_A\)Rs, potentiating GABA EC\(_{10}\)-evoked currents through these receptors to amplitudes 2-3 fold higher than the maximal responses of GABA (Figure 1B, Table 1). Interestingly, methaqualone displayed bell-shaped concentration-response curves as a PAM at all receptors when co-applied with GABA EC\(_{10}\) in concentrations ranging from 1 \(\mu\)M to 1000 \(\mu\)M (exemplified for \(\alpha_1\beta_2\gamma_2S\) and \(\alpha_6\beta_2\delta\) in Figures 1C and 1D). Furthermore, pronounced rebound currents were observed at methaqualone concentrations of 300 \(\mu\)M and above (Figure 1C).

To elucidate the nature of methaqualone-mediated modulation of \(\alpha\beta\gamma\) and \(\alpha\beta\delta\) GABA\(_A\)Rs, GABA concentration-relationships at the \(\alpha_1\beta_2\gamma_2S\) and \(\alpha_6\beta_2\delta\) receptors were determined in the absence or presence of the modulator. In agreement with previous studies (Campo-Soria et al., 2006; Gielen et al., 2012), the maximal current amplitude evoked by GABA through \(\alpha_1\beta_2\gamma_2S\) in presence of a saturating diazepam concentration (3 \(\mu\)M) (\(R_{\text{max}}\) ± S.E.M.: 110 ± 10 %, \(N = 4\)) did not differ significantly from that elicited by GABA alone, whereas the benzodiazepine gave rise to a small but significant (2.4-fold) left-shift of the concentration-response curve (EC\(_{50}\) [pEC\(_{50}\) ± S.E.M.]: 24 \(\mu\)M [4.62 ± 0.10] (\(N = 4\)) vs. 57 \(\mu\)M [4.25 ± 0.10] (\(N = 7\); \(p < 0.1\)) (Figure 1E). In contrast, pre-incubation and co-application of 300 \(\mu\)M methaqualone increased the potency of GABA at the receptor by 41-fold (EC\(_{50}\) [pEC\(_{50}\) ± S.E.M.]: 1.4 \(\mu\)M [5.85 ± 0.08] (\(N = 6\)) vs. 57 \(\mu\)M [4.25 ± 0.10] (\(N = 7\); \(p < 0.001\)), whereas the maximal response evoked by GABA was significantly reduced (\(R_{\text{max}}\) ± S.E.M.: 82 ± 2.3 % (\(N = 6\); \(p < 0.1\)) (Figure 1E). Interestingly, it was impossible to determine the effect of 300 \(\mu\)M methaqualone at the GABA concentration-response relationship at the \(\alpha_6\beta_2\delta\) receptor, since the large currents elicited through this receptor by co-applications of the modulator and high GABA concentrations consistently resulted in
failure to keep the holding potential of the oocytes. However, low GABA concentrations unable to evoke significant currents in $\alpha_6\beta_2\delta$-oocytes when applied alone were observed to induce substantial currents when co-applied with 300 µM methaqualone (data not shown). Thus, although we were unable to quantify the degree of left-shift of the GABA concentration-response curve brought on by the presence of methaqualone, the drug clearly modulated both GABA potency and efficacy at this receptor.

With the first round of characterization having revealed distinctly different methaqualone functionalities at different $\alpha$-containing GABA$\alpha$R subtypes, the second round was focused on the putative importance of $\beta$ subunit identity and of the accessory $\gamma_2S/\delta$ subunit for the modulation of $\alpha_1\beta\gamma_2S$ and $\alpha_4\beta\delta$ GABA$\alpha$Rs. The methaqualone-mediated potentiation of the $\alpha_1\beta\gamma_2S$ GABA$\alpha$Rs did not appear to be dependent on the presence of $\gamma_2S$ in the receptor, since the functionalities exhibited by the compound at $\alpha_1\beta_2$ and $\alpha_1\beta_2\gamma_2S$ receptors did not differ significantly (Figure 2A, Table 1). Furthermore, substituting $\beta_2$ for $\beta_3$ in the $\alpha_1\beta\gamma_2S$ complex did not change the potency or efficacy of methaqualone as a PAM substantially (Figure 2A, Table 1).

In contrast to its comparable modulation of $\alpha_1\beta_2\gamma_2S$ and $\alpha_1\beta_3\gamma_2S$ receptors, methaqualone displayed dramatically different functionalities at the different $\beta$ subunit-containing $\alpha_4\beta\delta$ and $\alpha_6\beta\delta$ subtypes. Contrary to its PAM activity at the $\alpha_4\beta_2\delta$ GABA$\alpha$R (Figure 1B), methaqualone did not modulate the responses evoked by GABA EC$_{10}$ or GABA EC$_{70}$ in $\alpha_4\beta_1\delta$-oocytes, and strikingly the presence of $\beta_3$ in the $\alpha_4\beta\delta$ complex converted the compound into a superagonist with an efficacy comparable to that of the orthosteric agonist THIP (Figures 2B and 2C, Table 1) (Hoestgaard-Jensen et al., 2014; Storustovu and Ebert, 2006). The origin of the agonism mediated by methaqualone at this receptor will be addressed further in the Discussion section.

The functional properties exhibited by methaqualone at the three $\alpha_6\beta\delta$ GABA$\alpha$Rs were just as
diverse as those at the αβδ receptors, but interestingly the pattern of functionalities determined for the modulator at these two receptor groups differed completely (Table 1). Methaqualone was a less efficacious PAM at α6β2δ than at the α6β2δ GABA_ARs, and the compound did not potentiate the GABA-evoked signaling through the α6β1δ GABA_AR but instead acted as a weak negative allosteric modulator (NAM) at the receptor (Figure 2D, Table 1). Finally, judging from the similar functional characteristics displayed by methaqualone at α6β2 and α6β2δ GABA_ARs, the presence of the δ subunit in the GABA_AR assembly did not seem to be important for its modulation of αβδ receptors (Figure 2D, Table 1).

**Delineation of the mechanism of action of methaqualone at the GABA_AR.** To elucidate the molecular basis for methaqualone modulation of the GABA_AR, we investigated the putative interactions of the modulator with four known allosteric sites in the receptor complex.

*The benzodiazepine site.* The high-affinity benzodiazepine site in the αβγ GABA_AR is located at the extracellular α(+)/γ(−) subunit interface (Sigel and Lüscher, 2011; Wieland et al., 1992). Although the similar potencies displayed by methaqualone at the numerous GABA_AR subtypes included in this study suggested that the modulator does not act through this site, the different structure of methaqualone compared to benzodiazepines could hypothetically enable it to bind to the α(+)/γ(−) interface in αβγ receptors as well as to the corresponding interfaces in αβ and αβδ GABA_ARs. This possibility was investigated by two different approaches.

In the first experiment, the effect of the benzodiazepine-site antagonist flumazenil on methaqualone-mediated potentiation of α1β2γ2S receptor signaling was assessed. In concordance with the literature (Sigel and Lüscher, 2011), preincubation and co-application of 10 μM flumazenil with GABA EC_{10} did not modulate the agonist-evoked response through the receptor significantly (10 ± 1.4 % (N = 13) vs. 13 ± 1.3 % (N = 13)), whereas the potentiation of the
GABA EC\textsubscript{10}-evoked response mediated by 3 \(\mu\)M diazepam (31 ± 3.7 %, \(N = 11\)) was completely eliminated by the presence of the antagonist (12 ± 1.4 %, \(N = 6\)) (Figure 3A). In contrast, 10 \(\mu\)M flumazenil did not reduce the methaqualone-mediated potentiation of \(\alpha_1\beta_2\gamma_2\text{S}\) GABA\(_A\)R signaling significantly (59 ± 3.5 % (\(N = 7\)) vs. 61 ± 4.2 % (\(N = 7\))) (Figure 3A).

In the second experiment, the impact of the \(\alpha_1\)-H102R mutation on the methaqualone-mediated modulation at \(\alpha_1\beta_2\gamma_2\text{S}\) receptor signaling was investigated. Substitution of this conserved histidine residue in the \(\alpha_1,2,3,5\)-subunit with an arginine (the corresponding residue in \(\alpha_4,6\)) has been shown to render \(\alpha_1,2,3,5\beta\gamma\) receptors insensitive to benzodiazepines (Sigel and Lüscher, 2011; Wieland et al., 1992). Whereas diazepam (3 \(\mu\)M) was observed to be completely inactive as a PAM at the \(\alpha_1^{\text{H102R}}\beta_2\gamma_2\text{S}\) GABA\(_A\)R, the potentiation of GABA EC\textsubscript{10} evoked-signaling through WT \(\alpha_1\beta_2\gamma_2\text{S}\) and \(\alpha_1^{\text{H102R}}\beta_2\gamma_2\text{S}\) receptors exerted by 300 \(\mu\)M methaqualone did not differ substantially (77 ± 2.1 % (\(N = 6\)) vs. 70 ± 2.1 % (\(N = 5\))) (Figure 3B). In conclusion, these findings unequivocally rule out the high-affinity benzodiazepine site as the site of action for methaqualone.

The barbiturate site. Although numerous residues and regions in GABA\(_A\)Rs have been shown to be important for the barbiturate-mediated modulation of the receptors, the exact location of the binding site(s) for these ago-PAMs in the receptors has yet to be identified (Chiara et al., 2013; Feng and Macdonald, 2010; Greenfield et al., 2002; Serafini et al., 2000). To assess whether methaqualone targets the barbiturate site or an overlapping site in the GABA\(_A\)R, we investigated whether the small but significant agonist response evoked by 300 \(\mu\)M pentobarbital through the \(\alpha_1\beta_2\gamma_2\text{S}\) receptor could be modulated by methaqualone. As can be seen in Figure 3C, the current amplitudes elicited by 300 \(\mu\)M methaqualone (1.2 ± 0.17 %, \(N = 6\)) and by 300 \(\mu\)M pentobarbital (4.9 ± 0.68 %, \(N = 6\)) at \(\alpha_1\beta_2\gamma_2\text{S}\)-expressing oocytes were significantly smaller than that arising
from co-application of the two compounds at the receptor (18 ± 1.7 %, N = 6). The ability of methaqualone to potentiate pentobarbital-evoked $\alpha_1\beta_2\gamma_2S$ signaling demonstrates that it binds to a site that does not overlap with the site through which the barbiturate mediates it direct activation of the receptor. However, in view of the presently limited insight into the molecular basis for barbiturate modulation of GABA$_A$Rs, we cannot exclude the possibility that barbiturate-mediated potentiation could arise from a distinct site in the GABA$_A$R, and that this site could overlap with the methaqualone binding site.

The neurosteroid sites. Several endogenous and synthetic neurosteroids act as potent ago-PAMs of GABA$_A$Rs (Herd et al., 2007). Smart and coworkers have proposed the existence of two discrete binding sites for neurosteroids in the transmembrane domains of the murine $\alpha_1\beta_2\gamma_2$ GABA$_A$R: an intersubunit site at the $\beta^{(+)}/\alpha^{(-)}$ subunit interface (comprising the $\alpha_1$-TM1 residue Thr$^{236}$) important for neurosteroid activation and an intrasubunit site in the $\alpha$ subunit (comprising the $\alpha_1$-TM1 residue Gln$^{241}$) important for both neurosteroid-mediated potentiation and activation (Hosie et al., 2009; Hosie et al., 2006). To investigate whether methaqualone mediates its effects on GABA$_A$R signaling through one or both of these sites, the impact of mutations of these two $\alpha_1$ residues (Thr$^{237}$ and Gln$^{242}$, human $\alpha_1$ numbering) on the modulation exerted by the compound at the $\alpha_1\beta_2\gamma_2S$ GABA$_A$R was determined. Allopregnanolone was used as reference compound in these recordings, and in concordance with previous studies the neurosteroid was found to be an efficacious PAM of the GABA$_A$R (Figure 3D). In contrast to previous findings, however, allopregnanolone did not exhibit significant intrinsic agonist activity at the receptor at concentrations up to 10 µM (Chen et al., 2014; Hosie et al., 2009; Hosie et al., 2006). The possible reasons for the absence of the direct activation component of allopregnanolone at the receptor are currently being investigated in our lab.
The absence of allopregnanolone-evoked agonism at the $\alpha_1\beta_2\gamma_2S$ receptor obviously precluded us from verifying the previously reported effects of $\alpha_1$-Q242W and $\alpha_1$-T237I mutations on this activity component of the neurosteroid. However, in agreement with the previously reported importance of a highly conserved Gln residue in TM1 of the $\alpha$ subunit for neurosteroid-mediated potentiation of GABA$_A$Rs (Hosie et al., 2009; Hosie et al., 2006), allopregnanolone was found to be completely inactive as a PAM at the $\alpha_1^{Q242W}\beta_2\gamma_2S$ receptor at concentrations up to 10 $\mu$M (Figure 3D). In contrast, the presence of 10 $\mu$M allopregnanolone potentiated GABA EC$_{10}$-evoked currents in WT $\alpha_1\beta_2\gamma_2S$- and $\alpha_1^{T237I}\beta_2\gamma_2S$-expressing oocytes to similar degrees, which is also in agreement with the findings by Hosie et al. (2006) and with the notion of the proposed intersubunit site being responsible for neurosteroid-mediated activation exclusively (Figure 3D). Interestingly, the degree of potentiation of the GABA EC$_{10}$-evoked response through the $\alpha_1\beta_2\gamma_2S$ receptor mediated by 300 $\mu$M methaqualone was not changed significantly by the introduction of neither the Q242W nor the T237I mutation in the $\alpha_1$ subunit (Figure 3D).

Although the functional implications of the two $\alpha_1$ mutations on allopregnanolone-mediated potentiation of the GABA$_A$R observed in this study are in concordance with those reported by the Smart group, the apparent discrepancy between our findings and the literature when it comes to the intrinsic agonist activity of the neurosteroid should obviously be kept in mind when interpreting the results obtained for methaqualone in these recordings. We propose that the dramatically different effects induced by the $\alpha_1$-Q242W mutation on the allopregnanolone- and methaqualone-mediated potentiation of $\alpha_1\beta_2\gamma_2S$ receptor signaling unequivocally demonstrate that methaqualone does not act through the proposed intrasubunit neurosteroid site in the receptor. As for the proposed intersubunit neurosteroid site, the lack of intrinsic agonist activity of allopregnanolone at $\alpha_1\beta_2\gamma_2S$ clearly devaluates it as a reference compound. Taken at face
value, however, the WT-like properties exhibited by methaqualone at the $\alpha_1^{T237I}\beta_2\gamma_2S$ receptor does suggest that the modulator does not target a site comprising this residue.

The transmembrane $\beta^{(+)}/\alpha^{(-)}$ subunit interface. The transmembrane $\beta^{(+)}/\alpha^{(-)}$ interface in the $\text{GABA}_A$R harbors binding sites for numerous allosteric modulators, but with the exception of the site targeted by the general anesthetic etomidate the compositions and locations of these sites are poorly elucidated (Bali and Akabas, 2004; Belelli et al., 1997; Halliwell et al., 1999; Hill-Venning et al., 1997; Khom et al., 2007; Krasowski et al., 2001; Thompson et al., 2004; Wafford et al., 1994; Walters et al., 2000). Interestingly, however, several of these modulators exhibit distinct selectivity between $\text{GABA}_A$R subtypes on the basis of their respective $\beta$-subunits (Belelli et al., 1997; Halliwell et al., 1999; Hill-Venning et al., 1997; Khom et al., 2007; Thompson et al., 2004; Wafford et al., 1994). In this light, the differential functionalities displayed by methaqualone at the different $\beta$-subunit containing $\alpha_4\beta\delta$ and $\alpha_6\beta\delta$ receptors were intriguing and prompted us to probe the putative importance of three transmembrane residues in the $\text{GABA}_A$R for the functional properties of methaqualone.

Residue 265 in TM2 of the $\beta$-subunit ($\beta_1$-Ser$^{265}$, $\beta_2/\beta_3$-Asn$^{265}$) is a key molecular determinant of the $\beta$-selectivity ($\beta_2/\beta_3$-over-$\beta_1$ or $\beta_1$-over-$\beta_2/\beta_3$) displayed by several of the $\beta^{(+)}/\alpha^{(-)}$ interface modulators (Belelli et al., 1997; Halliwell et al., 1999; Hill-Venning et al., 1997; Khom et al., 2007; Wingrove et al., 1994). In the case of etomidate, the residue is believed not to participate in binding but rather to act as a transduction element between modulator binding and its effect on gating (Chiara et al., 2012; Desai et al., 2009; Li et al., 2006; Stewart et al., 2013; Stewart et al., 2014). In agreement with previous studies (Belelli et al., 1997; Desai et al., 2009; Siegwart et al., 2002; Stewart et al., 2014), introduction of a N265M mutation in $\beta_2$ was observed to eliminate etomidate-mediated potentiation of $\alpha_1\beta_2\gamma_2S$ receptor signaling completely, and interestingly the
mutation had a similar detrimental effect on the methaqualone-mediated potentiation (Figure 4A). Furthermore, the PAM and NAM activities exhibited by methaqualone at the $\alpha_6\beta_2\delta$ and $\alpha_6\beta_1\delta$ receptors, respectively, were completely reversed by introduction of the reciprocal residue in position 265 of the respective $\beta$ subunits. In fact, methaqualone was roughly equipotent and equally efficacious as a PAM at the $\alpha_6\beta_2\delta$ and $\alpha_6\beta_1^{S265N}\delta$ receptors and as a NAM at $\alpha_6\beta_1\delta$ and $\alpha_6\beta_2^{N265S}\delta$ receptors (Figures 4B and 4C, Table 1).

Elaborate photolabeling, substituted cysteine accessibility method and mutagenesis studies have demonstrated the key importance of the $\alpha_1$-TM1 Met$^{236}$ and $\beta_2$-TM3 Met$^{286}$ residues for the GABAA$\gamma$R modulation exerted by etomidate, and the two residues are believed to form direct interactions with the modulator (Chiara et al., 2012; Li et al., 2006; Siegwart et al., 2002; Stewart et al., 2008; Stewart et al., 2013). In concordance with previous studies (Siegwart et al., 2002; Stewart et al., 2008), etomidate (100 µM) displayed higher intrinsic agonist activity at the $\alpha_1^{M236W}\beta_2\gamma_2S$ GABAA$\gamma$R than at the WT $\alpha_1\beta_2\gamma_2S$ receptor, whereas it was completely inactive at the $\alpha_1\beta_2^{M286W}\gamma_2S$ receptor (Figures 4D and 4E). Analogously to the increased intrinsic agonist activity of etomidate brought on by the $\alpha_1$-M236W mutation, the insignificant agonism of methaqualone at WT $\alpha_1\beta_2\gamma_2S$ was converted into pronounced agonist activity at the $\alpha_1^{M236W}\beta_2\gamma_2S$ receptor (Figure 4D). Conversely, the effect of the $\beta_2$-M286W mutation on methaqualone functionality was considerably subtler than that for etomidate, methaqualone being roughly equipotent albeit less efficacious as a PAM at the $\alpha_1\beta_2^{M286W}\gamma_2S$ GABAA$\gamma$R compared to the WT receptor (Figure 4E).

In a final experiment the modulation exerted by etomidate at the $\alpha_4\beta\delta$ GABAA$\delta$Rs was compared with the diverse functionalities exhibited by methaqualone at the three receptors. As mentioned above, etomidate acts as a PAM at a plethora of $\alpha_{1,2,3,6}\beta\gamma_2$ GABAA$\gamma$Rs, being ~10-fold
more potent and substantially more efficacious at β₂/β₃-containing than at β₁-containing subtypes of these receptors (Belelli et al., 1997; Hill-Venning et al., 1997). Etomidate has also been reported to potentiate GABA-evoked signaling through α₄β₃δ GABA_{A}Rs expressed in Xenopus oocytes and in mammalian cell lines (Brown et al., 2002; Jensen et al., 2013; Meera et al., 2009), but to our knowledge its modulatory effects at recombinant α₄β₁δ and α₄β₂δ receptors have not been reported. Etomidate (100 μM) displayed no significant agonist activity at the receptors formed in α₄β₁δ-expressing oocytes and only slightly higher intrinsic activity at the α₄β₂δ GABA_{A}R (R_{max} values of 1-5% of GABA R_{max}). However, the compound robustly potentiated GABA EC_{10}-evoked responses through the two receptors (Figure 5A). Conversely, etomidate (100 μM) was found to be a pronounced agonist at the α₄β₃δ GABA_{A}R, evoking a response ~4-fold higher than the GABA R_{max} at the receptor (Figure 5B). Although the fact that we only studied the effects of a single high etomidate concentration (100 μM) in these recordings combined with its reported bell-shaped concentration-response relationships at other GABA_{A}Rs (Belelli et al., 1997; Hill-Venning et al., 1997) preclude us from drawing conclusions regarding whether etomidate exhibits differential modulatory potencies and/or efficacies at the three α₄βδ receptors, the qualitative nature of its modulation of the receptors can be extracted from the data. Analogously to methaqualone, etomidate is a fairly pure PAM at α₄β₂δ and a superagonist at the α₄β₃δ receptor, whereas its PAM activity at the α₄β₁δ GABA_{A}R contrasts the inactivity of methaqualone at this subtype (at concentrations up to 300 μM).

Putative binding modes of etomidate, loreclezole and methaqualone. All in all, the results outlined above indicate that methaqualone acts through the same transmembrane β⁺/α⁻ interface in the GABA_{A}R complex targeted by etomidate, the anticonvulsant drug loreclezole and several other modulators. An analysis of the physical-chemical properties of etomidate,
loreclezole and methaqualone shows that the three compounds share notable structural similarities. Both etomidate and methaqualone comprise two hydrophobic moieties as well as a carbonyl group and aromatic nitrogen capable of acting as hydrogen bond acceptors (Figure 6A). Loreclezole comprises one hydrophobic moiety as well as a vinylogous chlorine and a triazole ring system as a potential hydrogen bond acceptors (Figure 6A). This similarity prompted us to compare the putative binding modes of the three modulators with the aim of defining one common pharmacophore.

In view of the relatively high functional potencies of etomidate, loreclezole and methaqualone as GABA<sub>A</sub>R modulators, all three modulators are expected to bind to the receptor in a low-energy conformation. Thus, the three molecules were initially submitted to a stochastic conformational search to enumerate their respective low-energy conformations. In the case of etomidate, the 2-phenethyl group adapted only one well-defined conformation, and although three rotamers of the ester alkyl group was found the energy differences between these were not significant (<1 kcal/mol). Methaqualone is also a highly rigid molecule, and its low-energy conformation was readily determined. The same was true for loreclezole, which adapted only one low-energy conformation. The low-energy conformations of the three molecules were superimposed based on the assumption that carbonyl groups of etomidate and methaqualone and the vinylogous chlorine of loreclezole dictate the binding modes of the respective compounds in the putative shared site (Figure 6B). From this overlay it is clear that the ester alkyl group of etomidate, the 2,4-diclorophenyl ring of loreclezole and the fused phenyl ring of methaqualone occupy the same area of space (designated hydrophobic pocket P1 in Figure 6A). The 2-phenethyl group of etomidate and the N-phenyl group of methaqualone are oriented in the same area of space (designated pocket P2 in Figure 6A). In this area loreclezole comprises a triazole ring, which in comparison with the corresponding moieties in etomidate and methaqualone is less
hydrophobic. Thus, the P2 pocket may be capable of accommodating the binding of ring systems with quite different physico-chemical properties. Finally, the aromatic nitrogen atoms in the three molecules do not align perfectly in this superimposition. However, reorganization of the water molecules in the binding pocket (induced fit) could possibly adjust for the differences in hydrogen bond donating trajectories of the respective nitrogen atoms. Thus, the in silico study seems to support the hypothesis that etomidate, loreclezole and methaqualone could bind to a common site in the transmembrane $\beta^{(+)}/\alpha^{(-)}$ interface of the GABA$_A$Rs, although it should be noted that the superimposition of etomidate and methaqualone is more successful than the loreclezole/etomidate and loreclezole/methaqualone superimpositions.

**Screening of methaqualone at other putative CNS targets.** The possible existence of other CNS targets for methaqualone than GABA$_A$Rs was investigated in an elaborate screening of the compound at a total of 50 recombinant neurotransmitter receptors and transporters and at native GABA$_A$Rs and ionotropic glutamate receptors in rat brain homogenates, a selection that includes numerous key targets for known psychotropic drugs and psychostimulants. For the majority of these targets the putative activity of methaqualone were assessed in competition binding assays (performed by PDSP), where radioligand concentrations near or at the $K_D$ value for the specific target in these assays was used to facilitate the detection of both inhibition and potentiation of radioligand binding by the test compound. Methaqualone (30 $\mu$M) did not display significant modulation (neither potentiation or inhibition) of radioligand binding to a wide range of serotonin, dopamine, norepinephrine, histamine, acetylcholine, glutamate, opioid, cannabinoid and sigma receptors or at the three monoamine transporters in these assays (Table 2). Furthermore, the compound was found to be inactive at concentrations up to 1 mM when tested
in functional assays at the other plasma membrane-bound targets for GABA: the GABA<sub>B</sub> receptors and GABA transporters (Table 2).

The inability of 30 µM methaqualone to compete with [³H]muscimol and [³H]flunitrazepam binding to rat brain tissue in the PDSP screening is in concordance with the binding site proposed for the modulator at GABA<sub>A</sub>Rs in this study. On the other hand, the insignificant modulation exerted by the compound on radioligand binding to native GABA<sub>A</sub>Rs in these assays could be argued to contrast the augmentation of radioligand binding to the orthosteric and the benzodiazepine binding sites in native GABA<sub>A</sub>Rs reported for other allosteric modulators of these receptors. Most notably in connection with methaqualone, both etomidate and loreclezole have been reported to enhance [³H]muscimol and [³H]flunitrazepam binding to rat brain tissue (Ghiani et al., 1996; Quast and Brenner, 1983; Sarantis et al., 2008; Slany et al., 1995; Xue et al., 1996; Zhong and Simmonds, 1997). However, not all modulators targeting a common binding site may necessarily be capable of modulating ligand binding to other sites in the receptors. Furthermore, the reported degrees of radioligand binding enhancement induced by etomidate and loreclezole in these studies vary considerably, and the modulation has not been observed in all studies (Green et al., 1996). Thus, specific assay conditions seem to influence whether or not putative modulation of binding is detected in a radioligand binding assay.

An obvious caveat connected to the use of the competition binding assays in this screening is that not all ligands targeting an allosteric site in a certain target necessarily will compete with or modulate orthosteric radioligand binding to it. However, the majority of targets assayed by radioligand binding in the screening were class A 7-transmembrane receptors (37 out of 48), and to our knowledge few (if any) allosteric modulators of these receptors have been reported not to affect orthosteric radioligand binding (Keov et al., 2011). Hence, although we cannot completely
exclude the possibility that methaqualone could target an allosteric site in one (or several) of the receptors, the inactivity of the drug in the binding assays is likely to be a true reflection of its pharmacology at them. In contrast, identification of ligands targeting multi-domain receptor complexes such as the GABA<sub>A</sub>Rs or ionotropic glutamate receptors in a competition binding assay is likely to be more dependent on the specific radioligand and/or experimental conditions used. Thus, the observed lack of effect of methaqualone on radioligand binding to these receptors should only be seen as a demonstration of the compound not binding to the specific site in the receptor complex targeted by the radioligand.

**Multiparametric description of the effects of methaqualone on cortical network activity in vitro.** To investigate the effects of methaqualone at native GABA<sub>A</sub>Rs and on neuronal network activity, the modulation exerted by the drug at the spontaneous activity pattern of primary neuronal networks from murine frontal cortex grown on MEA neurochips were analyzed by multiparametric data analysis. This technology has previously been used extensively for neurotoxicity studies (Gramowski et al., 2006b; Johnstone et al., 2010; Novellino et al., 2011) but also for functional phenotypic screening of drugs (Gramowski et al., 2006a; Gramowski et al., 2004; Parenti et al., 2013). The 204 activity-describing parameters calculated based on the spike trains from these recordings can be divided into four categories. Whereas “General Activity” parameters represent global network activity descriptors such as spike rate, burst rate, % of spikes in bursts and burst period, “Burst Structure” parameters describe the internal structure of spikes within a high-frequency spiking phase (e.g. spike frequency in bursts, spike rate in bursts, spike density) as well as the overall burst structure (e.g. duration, area, plateau). “Oscillatory Behavior” parameters are the standard deviations associated with main General Activity and Burst Structure parameters and illustrate the regularity of bursting events within experimental episodes, with higher values indicating less regular general activity or less regular
burst structure. Finally, the “Synchronicity” parameters include those representing the coefficient of variation over the network, thus reflecting the level of synchronization amongst the neurons. Representative spike raster plots and some of the abovementioned extractable parameters from these recordings are given in Figure 7.

Concentration-effect relationships for methaqualone and other GABA<sub>A</sub>R modulators in the network recordings. The overall profile of methaqualone in the recordings reflected in the 60 best-describing parameters was very characteristic for a CNS depressant (Figures 8 and 9). Application of the modulator in concentrations found to elicit significant effects at the recombinant GABA<sub>A</sub>Rs in the TEVC recordings (1-100 µM) resulted in significantly reduced spike and burst rates and increased the interval between bursts as well as the average burst period. Moreover, burst sizes were significantly reduced by the presence of these methaqualone concentrations (e.g. decreases in burst duration, burst area and burst amplitude) (Figures 8 and 9). The decreased variability observed for several of the Burst Structure parameters (e.g. burst area SD and burst spike number SD) indicated a more regular burst structure, whereas the overall bursting activity was observed to be more irregular (increase in burst rate SD, interburst interval SD, event period SD). Finally, increased network variability (e.g. burst rate CVnet and other CVnet parameters, decreased SynShare, the average number of units involved in population bursts) indicative of decreased synchronization within the network was observed at these modulator concentrations (Figures 8 and 9). Interestingly, submicromolar concentrations of methaqualone also mediated significant effects on network activity although these were very subtle (Figures 8 and 9).

The functional characteristics of methaqualone in the MEA recordings were compared to those exhibited by four other GABA<sub>A</sub>R modulators: the benzodiazepine diazepam, the barbiturate phenobarbital, the general anesthetic etomidate and DS2, a selective PAM of δ-
containing GABA_{A}Rs (Waﬀord et al., 2009). The multi-parametric effects mediated by diazepam, etomidate and phenobarbital at the cortical networks were very similar to those induced by methaqualone, the diﬀerent concentration-response relationships displayed by the four modulators being easily reconcilable with their diﬀerent potencies as a GABA_{A}R PAMs (Figures 8 and 9). However, while the qualitatively trend in the changes induced by methaqualone, diazepam, etomidate and phenobarbital was the same for the majority of parameters, but some interesting diﬀerences were observed. For example, high/saturating concentrations of etomidate or methaqualone induced more pronounced changes in some of the General Activity, Burst Structure and Oscillatory Behavior parameters than high/saturating concentrations of phenobarbital or diazepam (Figure 8). The general eﬀects of DS2 on cortical network activity were much more subtle than those produced by the four other modulators, but most of the changes induced by this PAM were characterized by the same qualitative directions of parameter changes (Figures 8 and 9).

Similarity analysis and classiﬁcation. To assess the extent to which eﬀects of methaqualone at neuronal network activity resembled those induced by other types of CNS drugs and neuroactive compounds and whether its in vivo properties potentially could be ascribed to additional activity components than its GABA_{A}R activity, the “phenotypic ﬁngerprint” of the drug was compared to those exhibited by 69 reference compounds. This similarity analysis compares characteristics and patterns of the eﬀects induced by the respective drugs on the activity-describing recording parameters, which means that compounds exhibiting diﬀerent degrees of eﬀects on a parameter can be classiﬁed as similar. The database compounds selected for the analysis in the present study comprised compounds targeting numerous diﬀerent neurotransmitter systems through various mechanisms and included several classes of clinically administered therapeutics, including antidepressants, antipsychotics, anticonvulsants, antisedatives, analgesics, anesthetics
and pro-cognitive drugs (Table 3). A training data set with the 204 spike train parameters was established using the data records for the 69 reference compounds, and subsequently the data records of methaqualone were classified as previously described (Parenti et al., 2013), resulting in a ranking list reflecting the functional similarity of each of the methaqualone concentrations with the database compounds. Thus, the effects mediated by specific methaqualone concentrations were compared to the profiles of each of the reference compounds, i.e. the averaged effects induced by multiple concentrations of the reference compound. With the exception of the classical antipsychotic drug chlorpromazine and the antidepressant amitriptyline, the database compounds giving rise to effects exhibiting the highest similarities to those mediated by methaqualone (1-100 µM) were GABA\(_A\)R PAMs (etomidate, diazepam, thiopental, clonazepam), NMDA receptor antagonists (MK801, memantine) and other CNS depressants (valproate, retigabine) (Figure 10).

**In vivo exposure and efficacy of methaqualone in seizure threshold and motor coordination assays.** To investigate to which extent the *in vitro* properties displayed by methaqualone at GABA\(_A\)Rs correlated with its *in vivo* efficacy, exposure studies of the drug were combined with testing of it in MEST and beam walk assays in mice using diazepam as a reference GABA\(_A\)R modulator (Figure 11).

In preliminary exposure studies, plasma and brain concentrations of methaqualone were determined 15, 30, 60 and 120 min after s.c. administration of 10 mg/kg of the drug, and since both concentrations peaked at 60 min this study design was used for the subsequent experiments. Following administration of 10, 30 and 100 mg/kg doses of methaqualone, plasma concentrations of the drug were determined to 2.79 ± 0.57 µg/ml, 12.3 ± 0.93 µg/ml and 26.7 ± 0.63 µg/ml, respectively, and brain concentrations to 0.71 ± 0.10 µg/g, 4.1 ± 0.23 µg/g and 16.1 ± 0.27 µg/g,
respectively (means ± SEM, N = 3). Since the free (unbound) fraction of methaqualone in mouse brain homogenate were determined to be 13%, corresponding unbound concentrations of methaqualone in brain were estimated to 0.37 ± 0.05 µM, 2.14 ± 0.12 µM and 8.38 ± 0.14 µM for the 10, 30 and 100 mg/kg doses, respectively (Figure 11A). Plasma and brain concentrations of the reference drug diazepam were not determined in this study. However, a previous study has found s.c. administration of 3 mg/kg diazepam in mice to produce a total brain concentration of 400 ng/g (30 min after administration) (Doran et al., 2005), and we have determined the fraction of free (unbound) diazepam in mouse brain to be 3%. Extrapolating from this, the 0.3, 1 and 3 mg/kg diazepam doses used in this study (Figure 11B) would correspond to brain free diazepam concentrations of approximately 4, 15 and 40 nM, respectively.

Both methaqualone and diazepam displayed significant effects in the two animal models. Whereas s.c. administration of 100 mg/kg methaqualone increased seizure threshold in the animals in the MEST assay significantly, administration of 30 or 100 mg/kg methaqualone resulted in significantly increased numbers of slips and falls in the beam walk assay (Figure 11A). Analogously, diazepam and other benzodiazepines in these models induced significant sedative/ataxia effects at lower doses than those required to produce significant anticonvulsant effects (Figure 11B and data not shown). The doses of the two drugs needed to induce sedative/ataxia and anticonvulsant effects could seem somewhat high at a first glance. However, it is well documented that behavioral readouts in rodents and humans upon drug treatment do not always correlate, something that has been ascribed to the substantially faster hepatic clearance and drug metabolism in rodents (Lave et al., 1999; Sharma and McNeill, 2009).
DISCUSSION

Investigations into the mechanisms of action of old CNS drugs hold interesting perspectives. While a drug may have been shelved for good reasons, new insights into the molecular basis for its clinical efficacy can open new avenues of drug development, as exemplified by the current interest in ketamine as a lead for novel antidepressants (Sanacora and Schatzberg, 2014). Moreover, these explorations can shed light on previous observations for the drug and its target and could potentially reinvent the drug as a useful pharmacological tool. In the present study, the notorious past and elusive mode of action of methaqualone (and other quaaludes) prompted us to explore the molecular basis underlying its therapeutic and recreational effects.

Methaqualone is a multifaceted GABA$_A$R modulator. Methaqualone was found to be a pan-active GABA$_A$R modulator exhibiting activity at 12 out of 13 GABA$_A$R subtypes (Table 1). Albeit a relatively pure PAM at most of these receptors, methaqualone exhibited everything from inactivity over negative or positive modulation to pronounced agonism within this selection of subtypes. Moreover, the nature of its potentiation of $\alpha_{1,2,3,5}\beta_{2,3}\gamma_2\delta$ and $\alpha_4\beta_2\delta/\alpha_6\beta_2\delta$ signaling differed, as it exclusively modulated GABA potency at the $\alpha\beta\gamma$ receptor whereas it increased both GABA potency and efficacy at the $\alpha\beta\delta$ receptor. The presence of $\gamma_2$ or $\delta$ in the GABA$_A$R was clearly not a prerequisite for methaqualone-mediated modulation, but these differential PAM characteristics must nevertheless be ascribed to the distinct functional properties of $\alpha\beta\gamma$ and $\alpha\beta\delta$ receptors. While the remarkable high-efficacious direct activation of the $\alpha_4\beta_3\delta$ receptor mediated by methaqualone could be a reflection of true allosteric agonism, we can not exclude that it could arise from potentiation of the pronounced spontaneous activity of this receptor, analogously to the mechanism proposed to underlie the apparent agonism displayed by DS2 at this receptor in a recent study (Jensen et al., 2013). The fact that etomidate also displays superagonism at $\alpha_4\beta_3\delta$
MOL #99291

seems to support this latter hypothesis. Conversely, the inability of both modulators to potentiate the constitutive activity exhibited by the α₄β₁δ receptor suggests that they could possess true intrinsic agonist activity at α₄β₃δ, or alternatively that the molecular basis for the spontaneous activity of α₄β₁δ may differ from that of α₄β₃δ (Figure 5).

The comparable functional potencies displayed by methaqualone as PAM, NAM or agonist at the various GABAₐRs suggest that the modulator targets a uniform binding site in the receptors, a hypothesis further supported by the complete reversal of its modulatory properties at the α₆β₁δ and α₆β₂δ receptors brought on by β₁-S265N and β₂-N265S mutations (Figures 4B and 4C). Thus, the diverse functionalities of methaqualone are more likely to arise from different energy barriers underlying allosteric transitions in the respective subtypes rather than from the modulator targeting different sites or having substantially different binding modes in the receptors. Although the inactivity of methaqualone at α₄β₁δ would constitute an outlier in this scenario if rooted in low binding affinity, the compound could also be envisioned to act as a neutral ligand (or silent allosteric modulator) at this subtype. We will refrain from further speculations about this, however, not having investigated the basis for the lack of modulation at this subtype. Analogously to the notion of methaqualone exerting its multifaceted pharmacology through an uniform site in the GABAₐRs, some benzodiazepine-site ligands display functional selectivity at α₁,₂,₃,₅βγ₂ receptors (Dawson et al., 2006; de Lucas et al., 2015) and allosteric modulators of other receptor types have also been shown to mediate subtype-specific modulation (Costa et al., 2010; Marlo et al., 2009; Mathiesen et al., 2003).

The bell-shaped concentration-response curves and rebound currents obtained for methaqualone at the GABAₐRs are very similar to those observed for other PAMs/ago-PAMs acting through the transmembrane receptor domains (Figures 1C and 1D) (Feng et al., 2004;
MOL #99291

Feng and Macdonald, 2004; Halliwell et al., 1999; Hill-Venning et al., 1997; Khom et al., 2007; Wooltorton et al., 1997). In several of these cases, the submaximal potentiation observed at high modulator concentrations has been attributed to the existence of a low-affinity open channel block site, with the rebound currents arising from the rapid unbinding of the modulator from this site (Feng et al., 2004; Halliwell et al., 1999; Khom et al., 2007; Wooltorton et al., 1997). This also seems a plausible explanation for methaqualone, although the submaximal potentiation at high modulator concentrations also could be caused by increased receptor desensitization.

*The methaqualone binding site.* Solid experimental evidence indicates that methaqualone does not act through the benzodiazepine, barbiturate or neurosteroid binding sites in the GABA<sub>A</sub>R (Figure 3). We propose that the key importance of β-subunit identity and of β-residue 265 for the functionality of methaqualone constitutes a strong case for the transmembrane β<sup>(γ)</sup>/α<sup>(γ)</sup> interface as the targeted receptor region. In contrast, there are compelling reasons to be cautious when speculating about the exact location of the binding site within this interface. Allosteric modulators have been found to bind quite differently to the transmembrane subunit interfaces in Cys-loop receptors (Hibbs and Gouaux, 2011; Lansdell et al., 2015; Sauguet et al., 2013; Stewart et al., 2013; Trattnig et al., 2012), and having only investigated two residues as putative binding partners we can hardly claim to have obtained a detailed insight into the binding mode of methaqualone. Albeit the changed modulation displayed by methaqualone at α<sub>1</sub><sup>M236W</sup>β<sub>2</sub>γ<sub>2S</sub> and α<sub>1</sub>β<sub>2</sub><sup>M286W</sup>γ<sub>2S</sub> receptors could indicate involvement of these residues in modulator binding, it could also arise from allosteric effects of the introduced mutations (Chiara et al., 2012; Siegwart et al., 2002). However, the structural similarities between methaqualone, etomidate and loreclezole and the common pharmacophore identified for them support the notion of a shared binding site (Figure 6), analogously to what has been proposed for etomidate, loreclezole and
mefenamic acid (Halliwell et al., 1999). Thus, these “β-residue 265 sensitive” modulators could be envisioned to act through such a common site, with ligands not sensitive to changes in this position possibly binding differently to this interface (Thompson et al., 2004).

**Functional characteristics of methaqualone at cortical neurons.** All in all, the effects of methaqualone on neuronal firing patterns in cortical networks seem to be reconcilable with its GABA<sub>A</sub>R activity, and comparison of these effects to those induced by other GABA<sub>A</sub>R modulators serves to elucidate the contributions from its different activity components (Figures 8 and 9). The four modulators targeting αβγ receptors (methaqualone, diazepam, etomidate and phenobarbital) all induced pronounced changes in the spontaneous activity patterns, and thus augmentation of synaptic GABA<sub>A</sub>R signaling appears to be key for overall effects on cortical network activity. In contrast, the much more subtle effects induced by DS2 indicate that the isolated contributions from δ-containing GABA<sub>A</sub>Rs to network activity are minor. Nevertheless, this activity component could be important for the observed effects of methaqualone, since potentiation of these extrasynaptic GABA<sub>A</sub>Rs would be expected to affect the firing threshold of the neurons.

The key role of GABA<sub>A</sub>Rs for the methaqualone-mediated effects is further supported by the high-ranking of several GABA<sub>A</sub>R PAMs, NMDA receptor antagonists and other known CNS depressants in the similarity analysis comparing the network activity effects of methaqualone to the phenotypic profiles of 69 reference compounds with diverse pharmacological and therapeutic properties (Figure 10, Table 3). The high-ranking of chlorpromazine constitutes a notable exception in this respect. Although micromolar chlorpromazine concentrations have been reported to modulate GABAergic currents in hippocampal neurons (Mozrzymas et al., 1999a; Mozrzymas et al., 1999b), it is a highly promiscuous drug with potent activity at numerous
receptors, transporters and ion channels, and thus its effects on neuronal network activity are likely to arise from several other mediators.

*Correlation between in vitro GABA<sub>A</sub>R activity and in vivo efficacy of methaqualone.* As discussed above, the negligible activity displayed by methaqualone a plethora of neurotransmitter targets in the screening and it effects on cortical network activity in the MEA recordings all in all seem to indicate that it is a fairly selective GABA<sub>A</sub>R modulator (Table 2, Figures 7-10). This prompted us to investigate whether its GABA<sub>A</sub>R activity could account for its *in vivo* efficacy. The estimated free (unbound) methaqualone concentrations in mouse brain arising from *in vivo* effective doses (2-8 µM) were in the very low end of the effective concentration range for the modulator at GABA<sub>A</sub>Rs in the TEVC recordings. This apparent mismatch is unlikely to arise from substantially different pharmacological properties of methaqualone at recombinant human and native rodent GABA<sub>A</sub>Rs, just as it seems improbable that its *in vivo* effects are mediated through another target. Instead, it could simply be a reflection of allosteric GABA<sub>A</sub>R modulators being efficacious *in vivo* at low levels of receptor occupancy. Interestingly, the estimated free concentrations of diazepam in mice brains produced by *in vivo* effective doses (4-40 nM) were also substantially lower than the functional potency of the benzodiazepine at recombinant αβγ GABA<sub>A</sub>Rs (EC<sub>50 ~ 100</sub> nM). In this light, our data could support the notion of GABA<sub>A</sub>Rs as the key mediators of the *in vivo* effects of methaqualone.

*Conclusion.* The present delineation of the molecular basis for the behavioral effects of methaqualone does more than confirm what has been assumed for decades: that the drug mediates these effects through GABA<sub>A</sub>Rs. Methaqualone exhibits distinct functional properties at the GABA<sub>A</sub>Rs compared to other allosteric modulators, and it mediates these through a different mechanism than the barbiturates and benzodiazepines that it historically has been
lumped together with. It is tempting to speculate that these differences could contribute to the reported differences in the \textit{in vivo} effects induced by methaqualone and classical CNS depressants. In any case, the multifaceted functionality of methaqualone at GABA\(_A\)Rs seems to be at the root of its clinical efficacy as well as the addiction liability and recreational misuse associated with the drug.
ACKNOWLEDGEMENTS

Dr. P.J. Whiting and MSD are thanked for the generous gifts of the human GABA<sub>A</sub>R cDNAs, and Dr. S. Mennerick is thanked for kind advice. The *in vitro* binding profiling of methaqualone was generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract #HHSN-271-2008-025C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth at the University of North Carolina at Chapel Hill and project officer Jamie Driscol at NIMH, Bethesda MD, USA.
AUTHOR CONTRIBUTIONS

Participated in research design: Hammer, Bader, Schroeder, Bastlund, Gramowski-Voß, and Jensen.

Conducted experiments: Hammer, Bader, Ehnert, Bundgaard, Bunch, and Jensen.

Performed data analysis: Hammer, Bader, Ehnert, Hoestgaard-Jensen, Bastlund, and Jensen.

Wrote the manuscript: Hammer, Bader, and Jensen (with contributions from Ehnert, Bundgaard, Bunch and Bastlund).
REFERENCES


de Lucas AG, Ahring PK, Larsen JS, Rivera-Arconada I, Lopez-Garcia JA, Mirza NR and Munro G (2015) GABA<sub>A</sub> α<sub>5</sub> subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity

41


Hicks TP, Kaneko T and Oka JI (1990) Receptive-field size of S1 cortical neurones is altered by methaqualone via a GABA mechanism. *Can J Neurol Sci* **17**: 30-34.


Mozrzymas JW, Barberis A, Michalak K and Cherubini E (1999b) Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABA<sub>\alpha</sub> receptors. *J Neurosci* **19**: 2474-2488.


Wingrove PB, Wafford KA, Bain C and Whiting P (1994) The modulatory action of loreclezole at the \(\gamma\)-aminobutyric acid type A receptor is determined by a single amino acid in the \(\beta\)2 and \(\beta\)3 subunit. Proc Natl Acad Sci USA \textbf{91}: 4569-4573.


Xue BG, Friend JM and Gee KW (1996) Loreclezole modulates \(^{35}\text{S}\)t-butyrbicyclonosphorothionate and \(^{3}\text{H}\)flunitrazepam binding via a distinct site on the GABA\textsubscript{A} receptor complex. Eur J Pharmacol \textbf{300}: 125-130.

This study was supported financially by the Novo Nordisk Foundation.
FIGURE LEGENDS

**Figure 1.** Functional properties of methaqualone at human GABA_ARs expressed in *Xenopus* oocytes. **A.** Chemical structure of methaqualone. **B.** Concentration-response curves for methaqualone at α_1β_2γ_2S, α_2β_2γ_2S, α_3β_2γ_2S, α_4β_2δ, α_5β_2γ_2S and α_6β_2δ GABA_ARs in the presence of GABA EC_10 (means ± S.E.M.; N = 5-9). **C.** Representative traces for various concentrations of methaqualone co-applied with GABA EC_10 at α_1β_2γ_2S (*left*) and α_6β_2δ (*right*) GABA_ARs. The application bars in grey for the various methaqualone concentrations all represent a 30 s pre-incubation with methaqualone followed by co-application of methaqualone and GABA EC_10. The black application bars represent application of GABA EC_10 and the GABA concentration eliciting the maximal response. **D.** Concentration-response curves for methaqualone at α_1β_2γ_2S and α_6β_2δ GABA_ARs in the presence of GABA EC_10 (means ± S.E.M.; N = 5-6). **E.** Concentration-response curves for GABA at the α_1β_2γ_2S GABA_AR in the absence or presence of 3 µM diazepam or 300 µM methaqualone (means ± S.E.M.; N = 4-6).

**Figure 2.** Functional properties of methaqualone at human GABA_ARs expressed in *Xenopus* oocytes. **A.** Concentration-response curves for methaqualone at α_1β_2, α_1β_2γ_2S and α_1β_3γ_2S GABA_ARs in the presence of GABA EC_10 (means ± S.E.M.; N = 6-7). **B.** Modulation of α_4β_1δ GABA_AR signaling exerted by methaqualone in the presence of GABA EC_10 or GABA EC_70 (means ± S.E.M.; N = 4-8). **C.** Representative trace and the concentration-response curve for methaqualone as an agonist at the α_4β_3δ GABA_AR (means ± S.E.M.; N = 6). The grey application bars above the trace indicate application of the various methaqualone concentrations, and the black bar represents application of a GABA concentration eliciting a maximal response.
D. **Left:** Concentration-response curves for methaqualone at $\alpha_6\beta_2$, $\alpha_6\beta_1\delta$, $\alpha_4\beta_2\delta$ and $\alpha_6\beta_3\delta$ GABA$_A$Rs in the presence of GABA EC$_{10}$ (means ± S.E.M.; N = 4-8). **Right:** Concentration-inhibition curve for methaqualone at the $\alpha_6\beta_1\delta$ GABA$_A$R in the presence of GABA EC$_{70}$ (means ± S.E.M.; N = 5). The hatched concentration-response curves for $\alpha_1\beta_2\gamma_2S$ and $\alpha_6\beta_2\delta$ in A and D, respectively, are based on data displayed in Figure 1B.

**Figure 3.** The potential interaction of methaqualone with three known allosteric sites of the GABA$_A$R complex. The experiments were performed at human WT and mutant $\alpha_1\beta_2\gamma_2S$ GABA$_A$Rs expressed in *Xenopus* oocytes. **A.** Effects of 10 $\mu$M flumazenil on the potentiation exerted by 3 $\mu$M diazepam or 300 $\mu$M methaqualone on the responses evoked by GABA EC$_{10}$ through the $\alpha_1\beta_2\gamma_2S$ GABA$_A$R. *Asterisks* indicate significant differences between responses evoked by GABA EC$_{10}$ in the presence of modulator (diazepam and methaqualone) and by GABA EC$_{10}$ alone, either in the absence or presence of flumazenil: ****, $p < 0.0001$ (means ± S.E.M.; N = 6-13). **B.** The modulatory effects of 3 $\mu$M diazepam and 300 $\mu$M methaqualone on the GABA EC$_{10}$-evoked responses through $\alpha_1\beta_2\gamma_2S$ and $\alpha_1^{H102R}\beta_2\gamma_2S$ GABA$_A$Rs. *Asterisks* indicate significant differences between responses evoked by GABA EC$_{10}$ in the presence of modulator and by GABA EC$_{10}$ alone at the same receptor (means ± S.E.M.; N = 5-12): ***, $p < 0.001$; ****, $p < 0.0001$. **C.** Direct activation of the $\alpha_1\beta_2\gamma_2S$ GABA$_A$R evoked by 300 $\mu$M methaqualone, by 300 $\mu$M pentobarbital and by co-application of 300 $\mu$M methaqualone and 300 $\mu$M pentobarbital (means ± S.E.M.; N = 7). *Asterisks* indicate the significant difference between the responses evoked by 300 $\mu$M pentobarbital and by co-application of 300 $\mu$M methaqualone and 300 $\mu$M pentobarbital: ****, $p < 0.0001$. **Inset:** Representative trace for direct activation of the $\alpha_1\beta_2\gamma_2S$ GABA$_A$R by 300 $\mu$M methaqualone, 300 $\mu$M pentobarbital and co-application of 300
µM methaqualone and 300 µM pentobarbital. D. The modulatory effects of 10 µM allopregnanolone and 300 µM methaqualone on the GABA EC\textsubscript{10} evoked responses through α\textsubscript{1}β\textsubscript{2}γ\textsubscript{2S}, α\textsubscript{1}\textsuperscript{T237I}β\textsubscript{2}γ\textsubscript{2S} and α\textsubscript{1}\textsuperscript{Q241W}β\textsubscript{2}γ\textsubscript{2S} GABA\textsubscript{A}Rs. Asterisks indicate significant differences between responses evoked by GABA EC\textsubscript{10} in the presence of modulator and by GABA EC\textsubscript{10} alone at the same receptor (means ± S.E.M.; N = 4-11): ****, p < 0.0001.

Figure 4. The potential interaction of methaqualone with the transmembrane β\textsuperscript{(+)}/α\textsuperscript{(-)} subunit interface in the GABA\textsubscript{A}R complex. The experiments were performed at human WT and mutant GABA\textsubscript{A}Rs expressed in Xenopus oocytes. A. Modulatory effects of 100 µM etomidate and 300 µM methaqualone on the responses evoked by GABA EC\textsubscript{10} through α\textsubscript{1}β\textsubscript{2}γ\textsubscript{2S} or α\textsubscript{1}β\textsubscript{2}\textsuperscript{N265M}γ\textsubscript{2S} GABA\textsubscript{A}Rs (means ± S.E.M.; N = 3-14). Asterisks indicate significant differences between the responses evoked by GABA EC\textsubscript{10} in the presence of modulator and by GABA EC\textsubscript{10} alone at the same receptor: ****, p < 0.0001. B. Concentration-response curves for methaqualone at α\textsubscript{6}β\textsubscript{2}δ and α\textsubscript{6}β\textsubscript{2}\textsuperscript{S265N}δ GABA\textsubscript{A}Rs in the presence of GABA EC\textsubscript{10} (means ± S.E.M.; N = 5). C. Left: Concentration-response curves for methaqualone at α\textsubscript{6}β\textsubscript{2}δ and α\textsubscript{6}β\textsubscript{2}\textsuperscript{N265S}δ GABA\textsubscript{A}Rs in the presence of GABA EC\textsubscript{10} (means ± S.E.M.; N = 3-8). Right: Concentration-inhibition curves for methaqualone at α\textsubscript{6}β\textsubscript{1}δ and α\textsubscript{6}β\textsubscript{2}\textsuperscript{N265S}δ GABA\textsubscript{A}Rs in the presence of GABA EC\textsubscript{60-70} (means ± S.E.M.; N = 5-7). D. Left: Direct activation of α\textsubscript{1}β\textsubscript{2}γ\textsubscript{2S} and α\textsubscript{1}β\textsubscript{2}\textsuperscript{M236W}γ\textsubscript{2S} GABA\textsubscript{A}R signaling evoked by 100 µM etomidate and 300 µM methaqualone (means ± S.E.M.; N = 4-8). Asterisks indicate significant differences between the responses evoked by etomidate or methaqualone at the two receptors: ****, p < 0.0001 (unpaired two-sided t-test). Right: Concentration-response curve for methaqualone as an agonist at the α\textsubscript{1}β\textsubscript{2}\textsuperscript{M236W}γ\textsubscript{2S} GABA\textsubscript{A}R (mean ± S.E.M.; N = 4). (E) Left: Modulatory effects of 100 µM etomidate and 300 µM methaqualone on the responses
evoked by GABA EC$_{10}$ at $\alpha_1\beta_2\gamma_2S$ and $\alpha_1\beta_2^{M286W}\gamma_2S$ GABA$_A$Rs (means ± S.E.M.; N = 3-10). Asterisks indicate significant differences between the responses evoked by GABA EC$_{10}$ in the presence of modulator and by GABA EC$_{10}$ alone at the same receptor: ****, $p < 0.0001$; ***, $p = < 0.001$. Right: Concentration-response curves for methaqualone at $\alpha_1\beta_2\gamma_2S$ and $\alpha_1\beta_2^{M286W}\gamma_2S$ GABA$_A$Rs in the presence of GABA EC$_{10}$ (means ± S.E.M.; N = 5-7). The hatched concentration-response curves for $\alpha_4\beta_1\delta$ (B) $\alpha_4\beta_2\delta$ (C) and $\alpha_1\beta_2\gamma_2S$ (E) are based on data in Figures 2D, 1B and 1B, respectively.

**Figure 5.** Functional properties of 100 $\mu$M etomidate at human $\alpha_4\beta\delta$ GABA$_A$Rs expressed in *Xenopus* oocytes. The modulation exerted by etomidate and methaqualone was determined at the same $\alpha_4\beta_1\delta$-, $\alpha_4\beta_2\delta$- or $\alpha_4\beta_3\delta$-expressing oocytes. A. Modulatory effects of 100 $\mu$M etomidate and 300 $\mu$M methaqualone on the responses evoked by GABA EC$_{10}$ through $\alpha_4\beta_1\delta$ or $\alpha_4\beta_2\delta$ GABA$_A$Rs. Responses given as means ± S.E.M in % of $R_{\text{max}}$ of GABA; etomidate: $118 \pm 9$ ($\alpha_4\beta_1\delta$, N = 6) and $195 \pm 23$ ($\alpha_4\beta_2\delta$, N = 4); methaqualone: $16 \pm 1.7$ ($\alpha_4\beta_1\delta$, N = 6) and $154 \pm 11$ ($\alpha_4\beta_2\delta$, N = 4). ****, $p < 0.0001$. B. Direct activation of the $\alpha_4\beta_3\delta$ GABA$_A$R by 100 $\mu$M etomidate or 300 $\mu$M methaqualone. Responses given as means ± S.E.M in % of $R_{\text{max}}$ of GABA; etomidate: $410 \pm 88$; N = 6; methaqualone: $437 \pm 74$; N = 6.

**Figure 6.** The putative shared binding mode of etomidate, loreclezole and methaqualone. A. Illustration of the structural similarities between etomidate (left), loreclezole (middle) and methaqualone (right). The putative pockets P1 and P2 are given in blue and the hydrogen bond acceptors in the compounds are indicated with red arrows. B. Superimposition of low-energy
conformations of etomidate (type code), loreclezole (pink) and methaqualone (green) by fitting the carbonyl groups of etomidate and methaqualone and the vinylogous chlorine of loreclezole.

**Figure 7.** Multiparametric analysis of cortical neuron network activity. *Top panels:* Representative spike raster plots of native cortical activity and cortical activity after acute treatment with 100 µM methaqualone. Reduction of overall spiking and bursting activity as well as reduction of burst strength is observed (higher magnification). *Bottom panel:* Scheme of two simplified bursts outlining some of the parameters that can be extracted from the recordings. Parameters describing general activity (burst inter burst interval (IBI) and burst period) and burst structure (burst duration, burst plateau, burst amplitude, burst inter spike interval (ISI) and burst area) are indicated. Standard deviations of these parameters such as SD of burst rate and SD of burst duration are measures for regularity of general activity and burst structure, respectively.

**Figure 8.** Summary of the changes induced by methaqualone, DS2, diazepam, phenobarbital and etomidate on cortical network activity in vitro. The heat maps present the significant changes in 60 activity-describing parameters from four defined categories arising from 8-9 cumulatively increasing concentrations of the five modulators (concentrations are given in M). The colors encode statistically significant modulator-induced changes (increases or decreases) in parameters relative to native activity (no drug, 100%).

**Figure 9.** Selected functional effects of methaqualone, DS2, etomidate, phenobarbital and diazepam on cortical network activity in vitro. The effects of 8-9 cumulatively increasing concentrations of methaqualone (MTQ - black square, blue line), DS2 (DS2 - gray triangle, gray line), phenobarbital (PHE - filled circle, black line), diazepam (DIA - open circle, green line) and
etomidate (ETO - black diamond, red line) at 16 activity-describing parameters from 4 defined categories. Data are given as mean ± SEM (relative to native activity).

**Table 10.** Similarity analysis of the effects of methaqualone at cortical network activity. Top 10 ranks of the most phenotypically similar functional profiles of 69 reference compounds from the NeuroProof database (listed in Table 3) ranked based on the similarity score for methaqualone at concentrations ranging from 1 µM to 100 µM. Data for the methaqualone concentrations 1 nM, 10 nM and 100 nM are given in shaded colors. The concentration-response profiles of the 69 reference compounds were used for training the classifier, and the methaqualone datasets was classified per concentration (10 per concentration). Table values correspond to similarity score per concentration (e.g. at 100 µM methaqualone, 8 % of its datasets were classified as etomidate, 4 % as diazepam, 12 % as chlorpromazine, etc.). High values reflect high functional phenotypic similarity between reference compound effects and methaqualone effects.

**Figure 11.** Sedative/ataxic effects and anticonvulsant efficacy of methaqualone (A) and diazepam (B) in beam walk and maximal electroshock seizure threshold (MEST) assays in mice. Data are given as average slips and falls (mean ± S.E.M.) and by the average current threshold (mean ± S.E.M.), respectively. * P<0.05 ANOVA and post hoc Dunnetts test.
Table 1. Functional properties of GABA and methaqualone determined by two-electrode voltage clamp electrophysiology at human GABA$_A$Rs expressed in *Xenopus* oocytes.

<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GABA</td>
<td></td>
<td>Methaqualone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EC$<em>{50}$ [pEC$</em>{50}$ ± S.E.M.]</td>
<td>N</td>
<td>EC$<em>{50}$ [pEC$</em>{50}$ ± S.E.M.]</td>
<td>R$_{max}$ ± S.E.M.</td>
<td>N</td>
</tr>
<tr>
<td>$\alpha_1\beta_2$</td>
<td>7.8 [5.11 ± 0.05]</td>
<td>6</td>
<td>49 [4.31 ± 0.03]</td>
<td>79 ± 3.7</td>
<td>6</td>
</tr>
<tr>
<td>$\alpha_1\beta_2\gamma_2S$</td>
<td>57 [4.25 ± 0.10]</td>
<td>6</td>
<td>38 [4.41 ± 0.03]</td>
<td>84 ± 2.1</td>
<td>7</td>
</tr>
<tr>
<td>$\alpha_1\beta_2\gamma_2S$</td>
<td>34 [4.46 ± 0.18]</td>
<td>5</td>
<td>30 [4.52 ± 0.03]</td>
<td>77 ± 2.2</td>
<td>6</td>
</tr>
<tr>
<td>$\alpha_2\beta_2\gamma_2S$</td>
<td>40 [4.40 ± 0.07]</td>
<td>4</td>
<td>24 [4.61 ± 0.03]</td>
<td>75 ± 2.1</td>
<td>9</td>
</tr>
<tr>
<td>$\alpha_3\beta_2\gamma_2S$</td>
<td>120 [3.94 ± 0.03]</td>
<td>7</td>
<td>49 [4.31 ± 0.12]</td>
<td>66 ± 2.4</td>
<td>4</td>
</tr>
<tr>
<td>$\alpha_4\beta_1\delta^a$ <em>monophasic</em></td>
<td>0.46 [6.33 ± 0.44]</td>
<td>3</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>$\alpha_4\beta_1\delta^a$ <em>biphasic</em></td>
<td>0.034 [7.47 ± 0.54]</td>
<td></td>
<td>1.2 [5.91 ± 0.51]</td>
<td>n.d.</td>
<td>4</td>
</tr>
<tr>
<td>$\alpha_4\beta_2\delta$</td>
<td>2.2 [5.65 ± 0.10]</td>
<td>7</td>
<td>68 [4.17 ± 0.06]</td>
<td>240 ± 27</td>
<td>5</td>
</tr>
<tr>
<td>$\alpha_4\beta_3\delta$</td>
<td>0.012 [7.94 ± 0.16]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This article has not been copyedited and formatted. The final version may differ from this version.
<table>
<thead>
<tr>
<th>Receptor</th>
<th>EC50 [μM]</th>
<th>pEC50 ± S.E.M.</th>
<th>Rmax (%)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>α5β2γ2S</td>
<td>3.1 [5.51 ± 0.14]</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>α3β1δ</td>
<td>1.4 [5.85 ± 0.08]</td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>α4β2</td>
<td>0.28 [6.54 ± 0.07]</td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>α4β2δ</td>
<td>0.30 [6.52 ± 0.04]</td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>α4β3δ</td>
<td>0.60 [6.23 ± 0.03]</td>
<td></td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>α1M236Wβ2γ2S</td>
<td>4.1 [5.39 ± 0.11]</td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>α1β2M286Wγ2S</td>
<td>5.4 [5.26 ± 0.07]</td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>α4β1S265Nδ</td>
<td>0.90 [6.05 ± 0.02]</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>α4β2N265Sδ</td>
<td>0.30 [6.53 ± 0.02]</td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>α20 [3.91 ± 0.14]</td>
<td>230 ± 12</td>
<td>6&lt;sup&gt;bc&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~100 [-4.0]</td>
<td>73 ± 1.6</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74 [4.13 ± 0.02]</td>
<td>220 ± 25</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36 [4.44 ± 0.04]</td>
<td>280 ± 22</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31 [4.50 ± 0.04]</td>
<td>110 ± 21</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>88 [4.06 ± 0.03]</td>
<td>60 ± 4.8</td>
<td>4&lt;sup&gt;bc&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 [4.60 ± 0.22]</td>
<td>41 ± 2.6</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96 [4.02 ± 0.03]</td>
<td>230 ± 24</td>
<td>5&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>~300 [-3.5]</td>
<td></td>
<td>7&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Unless otherwise indicated, data given for methaqualone represents its properties as a positive allosteric modulator determined at the receptors in the presence of GABA EC10. EC50 values are given in μM with pEC50 ± S.E.M. values in brackets, and Rmax values are given in % of the Rmax value of GABA at the receptor. N indicates the numbers of experiments performed.

n.d.: not determinable. <sup>a</sup> GABA displayed monophasic and biphasic concentration-response curves at three and four out of seven α4β1δ-expressing oocytes, respectively. Methaqualone was tested as a positive and negative allosteric modulator at both oocyte populations. <sup>b</sup> Properties...
of methaqualone as an agonist at $\alpha_4\beta_3\delta$ and $\alpha_4^{M236W}\beta_2\gamma_2$ GABA$_A$Rs (grey background). Agonist EC$_{50}$ values are given in $\mu$M with pEC$_{50} \pm$ S.E.M. values in brackets, and R$_{max}$ values are given in % of the R$_{max}$ value of GABA at the receptor. c The concentration-response curve was not completely saturated at the highest methaqualone concentration tested. EC$_{30}$ (pEC$_{50}$) and R$_{max}$ values have been extracted from the fitted curve. Properties of methaqualone as a negative allosteric modulator at $\alpha_6\beta_1\delta$ and $\alpha_6^{N265S}\delta$ GABA$_A$Rs determined in the presence of GABA EC$_{60-70}$ (black background). Estimated IC$_{50}$ values are given in $\mu$M with pIC$_{50}$ in brackets.
Table 2. Pharmacological properties of methaqualone at various CNS targets.

<table>
<thead>
<tr>
<th>Target</th>
<th>Assay</th>
<th>IC$_{50}$ [µM] (% inhibition)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serotonin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-HT$_{1A}$ (h)</td>
<td>$[^3]$H]8-OH-DPAT Binding</td>
<td>&gt;30 (6.3)</td>
</tr>
<tr>
<td>5-HT$_{1B}$ (h)</td>
<td>$[^3]$H]GR125743 Binding</td>
<td>&gt;30 (-1.3)</td>
</tr>
<tr>
<td>5-HT$_{1D}$ (h)</td>
<td>$[^3]$H]GR125743 Binding</td>
<td>&gt;30 (7.6)</td>
</tr>
<tr>
<td>5-HT$_{1e}$ (h)</td>
<td>$[^3]$H]5-HT Binding</td>
<td>&gt;30 (-11)</td>
</tr>
<tr>
<td>5-HT$_{2A}$ (h)</td>
<td>$[^3]$H]Ketanserin Binding</td>
<td>&gt;30 (-2.1)</td>
</tr>
<tr>
<td>5-HT$_{2B}$ (h)</td>
<td>$[^3]$H]LSD Binding</td>
<td>&gt;30 (-8.3)</td>
</tr>
<tr>
<td>5-HT$_{2C}$ (h)</td>
<td>$[^3]$H]Mesulergine Binding</td>
<td>&gt;30 (3.3)</td>
</tr>
<tr>
<td>5-HT$_{3A}$ (h)</td>
<td>$[^3]$H]LY278584 Binding</td>
<td>&gt;30 (-7.7)</td>
</tr>
<tr>
<td>5-HT$_{5a}$ (h)</td>
<td>$[^3]$H]LSD Binding</td>
<td>&gt;30 (-11)</td>
</tr>
<tr>
<td>5-HT$_{6}$ (h)</td>
<td>$[^3]$H]LSD Binding</td>
<td>&gt;30 (3.6)</td>
</tr>
<tr>
<td>5-HT$_{7}$ (h)</td>
<td>$[^3]$H]LSD Binding</td>
<td>&gt;30 (0.9)</td>
</tr>
<tr>
<td>SERT (h)</td>
<td>$[^3]$H]Citalopram Binding</td>
<td>&gt;30 (-1.5)</td>
</tr>
<tr>
<td>Dopamine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D$_1$ (h)</td>
<td>$[^3]$H]SCH23390 Binding</td>
<td>&gt;30 (-2.4)</td>
</tr>
<tr>
<td>D$_2$ (h)</td>
<td>$[^3]$H]N-Methylspiperone Binding</td>
<td>&gt;30 (30)</td>
</tr>
<tr>
<td>D$_3$ (h)</td>
<td>$[^3]$H]N-Methylspiperone Binding</td>
<td>&gt;30 (9.9)</td>
</tr>
<tr>
<td>D$_4$ (h)</td>
<td>$[^3]$H]N-Methylspiperone Binding</td>
<td>&gt;30 (10)</td>
</tr>
<tr>
<td>D$_5$ (h)</td>
<td>$[^3]$H]SCH23390 Binding</td>
<td>&gt;30 (11)</td>
</tr>
<tr>
<td>DAT (h)</td>
<td>$[^3]$H]WIN35428 Binding</td>
<td>&gt;30 (28)</td>
</tr>
</tbody>
</table>
Norepinephrine

\( \alpha_{1A} \) (h) \[^{3}\text{H}]\text{Prazosin Binding} \quad >30 \ (-12) \\
\( \alpha_{1B} \) (h) \[^{3}\text{H}]\text{Prazosin Binding} \quad >30 \ (5.6) \\
\( \alpha_{1D} \) (h) \[^{3}\text{H}]\text{Prazosin Binding} \quad >30 \ (47) \\
\( \alpha_{2A} \) (h) \[^{3}\text{H}]\text{Rauwolscine Binding} \quad >30 \ (45) \\
\( \alpha_{2B} \) (h) \[^{3}\text{H}]\text{Rauwolscine Binding} \quad >30 \ (3.4) \\
\( \alpha_{2C} \) (h) \[^{3}\text{H}]\text{Rauwolscine Binding} \quad ~30 \ (63) \\
\( \beta_{1} \) (h) \[^{125}\text{I}]\text{Pindolol Binding} \quad >30 \ (-5.8) \\
\( \beta_{2} \) (h) \[^{3}\text{H}]\text{CGP 12177 Binding} \quad >30 \ (-9.4) \\
\( \beta_{3} \) (h) \[^{3}\text{H}]\text{CGP 12177 Binding} \quad >30 \ (23) \\
NET (h) \[^{3}\text{H}]\text{Nisoxetine Binding} \quad >30 \ (2.3) \\

Histamine

H\(_{1}\) (h) \[^{3}\text{H}]\text{Pyrilamine Binding} \quad >30 \ (31) \\
H\(_{3}\) (h) \[^{3}\text{H}]\text{\(\alpha\)}\text{-methylhistamine Binding} \quad >30 \ (-9.5) \\

Acetylcholine

m\(_{1}\) (h) \[^{3}\text{H}]\text{QNB Binding} \quad >30 \ (-9.5) \\
m\(_{2}\) (h) \[^{3}\text{H}]\text{QNB Binding} \quad >30 \ (-4.8) \\
m\(_{3}\) (h) \[^{3}\text{H}]\text{QNB Binding} \quad >30 \ (-13) \\
m\(_{4}\) (h) \[^{3}\text{H}]\text{QNB Binding} \quad >30 \ (-17) \\
m\(_{5}\) (h) \[^{3}\text{H}]\text{QNB Binding} \quad >30 \ (13) \\
\# \( \alpha_{4}\beta_{2} \) (m) FLIPR Membrane Potential Assay \quad \text{EC}_{50} >1000, \text{IC}_{50} >1000 \\

GABA

Rat forebrain \[^{3}\text{H}]\text{Muscimol Binding} \quad >30 \ (-8.9)
MOL #99291

<table>
<thead>
<tr>
<th>Class</th>
<th>Subclass</th>
<th>Ligand</th>
<th>Affinity</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat brain</td>
<td>[3H]Flunitrazepam Binding</td>
<td>&gt;30 (-11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat periph. BZD rec.</td>
<td>[3H]PK11195 Binding</td>
<td>&gt;30 (21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAT1 (h)</td>
<td>[3H]GABA Uptake</td>
<td>&gt;1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BGT1 (h)</td>
<td>[3H]GABA Uptake</td>
<td>&gt;1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAT2 (h)</td>
<td>[3H]GABA Uptake</td>
<td>&gt;1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAT3 (h)</td>
<td>[3H]GABA Uptake</td>
<td>&gt;1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GABA_{Bla,2} (r)</td>
<td>Ca^{2+}/Fluo4 Assay (with Gqi5)</td>
<td>EC_{50} &gt;1000, IC_{50} &gt;1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GABA_{B1b,2} (r)</td>
<td>Ca^{2+}/Fluo4 Assay (with Gqi5)</td>
<td>EC_{50} &gt;1000, IC_{50} &gt;1000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Glutamate**

<table>
<thead>
<tr>
<th>Class</th>
<th>Ligand</th>
<th>Affinity</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat brain NMDA-R</td>
<td>[3H]MK801 Binding</td>
<td>&gt;30 (8.1)</td>
<td></td>
</tr>
<tr>
<td>Rat brain AMPA-R</td>
<td>[3H]AMPA Binding</td>
<td>&gt;30 (23)</td>
<td></td>
</tr>
<tr>
<td>Rat brain KA-R</td>
<td>[3H]KA Binding</td>
<td>&gt;30 (18)</td>
<td></td>
</tr>
</tbody>
</table>

**Opioid**

<table>
<thead>
<tr>
<th>Class</th>
<th>Ligand</th>
<th>Affinity</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>δ (h)</td>
<td>[3H]DADLE Binding</td>
<td>&gt;30 (34)</td>
<td></td>
</tr>
<tr>
<td>κ (h)</td>
<td>[3H]U69593 Binding</td>
<td>&gt;30 (4.9)</td>
<td></td>
</tr>
<tr>
<td>μ (h)</td>
<td>[3H]DAMGO Binding</td>
<td>~30 (50)</td>
<td></td>
</tr>
</tbody>
</table>

**Cannabinoid**

<table>
<thead>
<tr>
<th>Class</th>
<th>Ligand</th>
<th>Affinity</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB1 (h)</td>
<td>[3H]CP55940 Binding</td>
<td>~30 (54)</td>
<td></td>
</tr>
<tr>
<td>CB2 (h)</td>
<td>[3H]CP55940 Binding</td>
<td>&gt;30 (6.6)</td>
<td></td>
</tr>
</tbody>
</table>

**Sigma**

<table>
<thead>
<tr>
<th>Class</th>
<th>Ligand</th>
<th>Affinity</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sigma1 (rat brain)</td>
<td>[3H]Pentazocine(+) Binding</td>
<td>&gt;30 (-16)</td>
<td></td>
</tr>
<tr>
<td>Sigma2 (rat, PC12)</td>
<td>[3H]DTG Binding</td>
<td>&gt;30 (49)</td>
<td></td>
</tr>
</tbody>
</table>
The binding affinities for methaqualone at numerous targets in a competition binding assays (using radioligand concentrations near or at the $K_D$ value for the specific target) were determined by NIMH Psychoactive Drug Screening Program (PDSP). The IC$_{50}$ values obtained for methaqualone in the binding assays given in $\mu$M, and % inhibition or % potentiation of radioligand binding at 30 $\mu$M methaqualone is given in parentheses (positive and negative values represent % inhibition and % potentiation of control, respectively). An inhibition of >50% is considered significant by the PDSP. The data are based on 4 independent determinations. The functional properties of methaqualone at selected transporters and receptors determined in in-house functional assays. The IC$_{50}$ and EC$_{50}$ values obtained for methaqualone in these functional assays are given in $\mu$M. h, human; r, rat; m, mouse.
Table 3. The 69 NeuroProof database compounds compared to methaqualone in the similarity analysis.

<table>
<thead>
<tr>
<th>Acetaminophen</th>
<th>Epibatidine</th>
<th>Muscimol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agmatine</td>
<td>Eserine</td>
<td>Olanzapine</td>
</tr>
<tr>
<td>Amisulpride</td>
<td>Etomidate</td>
<td>Oxotremorine</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Flumazenil</td>
<td>Pentylenehetrazolium</td>
</tr>
<tr>
<td>AMPA</td>
<td>Flunitrazepam</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Apomorphine</td>
<td>Fluoxetine</td>
<td>Picrotoxin</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>GABA</td>
<td>Propofol</td>
</tr>
<tr>
<td>Atropine</td>
<td>Galanthamine</td>
<td>Quetiapine</td>
</tr>
<tr>
<td>Baclofen</td>
<td>GS 39783</td>
<td>Retigabine</td>
</tr>
<tr>
<td>Benzoquinone</td>
<td>Haloperidol</td>
<td>Risperidone</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Ibuprofen</td>
<td>SB 205384</td>
</tr>
<tr>
<td>CGP 7930</td>
<td>Indatraline</td>
<td>SCH 50911</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>L-655708</td>
<td>SKF-97541</td>
</tr>
<tr>
<td>CL218872</td>
<td>L-838417</td>
<td>Sufentanil</td>
</tr>
<tr>
<td>Clobazam</td>
<td>Lamotrigine</td>
<td>Thiopental</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>Levetiracetam</td>
<td>Thio-THIP</td>
</tr>
<tr>
<td>Clozapine</td>
<td>L-Polamidon</td>
<td>THIP</td>
</tr>
<tr>
<td>“Control”</td>
<td>LY341495</td>
<td>Topiramate</td>
</tr>
<tr>
<td>D-Cycloserine</td>
<td>LY354740</td>
<td>Tramadol</td>
</tr>
<tr>
<td>Diazepam</td>
<td>LY393558</td>
<td>Valproate</td>
</tr>
<tr>
<td>DMSO</td>
<td>Memantine</td>
<td>Wortmannin</td>
</tr>
<tr>
<td>MOL #99291</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Donepezil</strong></td>
<td><strong>MK801</strong></td>
<td><strong>Xli093</strong></td>
</tr>
<tr>
<td><strong>DS2</strong></td>
<td><strong>Morphine</strong></td>
<td><strong>Zolpidem</strong></td>
</tr>
</tbody>
</table>

---

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Native Activity

100 µM Methaqualone

Burst Amplitude
Burst Plateau
Burst Area
Burst Duration
Burst IBI
Burst Period
Burst ISI

60 sec
Figure 8

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 9

General Activity

Spike rate

Burst rate

Burst period

% spikes in bursts

Molecular Pharmacology Fast Forward. Published on June 8, 2015 as DOI: 10.1124/mol.115.099291

Burst Structure

Burst duration

Burst amplitude

Burst spike number

Burst spike density

Molecular Pharmacology Fast Forward. Published on June 8, 2015 as DOI: 10.1124/mol.115.099291

Oscillatory Behavior

Spike rate SD

Burst rate SD

Burst area SD

Burst spike number SD

Molecular Pharmacology Fast Forward. Published on June 8, 2015 as DOI: 10.1124/mol.115.099291

Synchronicity

Spike rate CVnet

Burst Rate CVnet

Burst duration CVnet

Syn share Mean

Molecular Pharmacology Fast Forward. Published on June 8, 2015 as DOI: 10.1124/mol.115.099291

This article has not been copyedited and formatted. The final version may differ from this version.
## Figure 10

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Etomidate (1E-11 - 3E-05 M)</td>
<td>2%</td>
<td>3%</td>
<td>4%</td>
<td>7%</td>
<td>6%</td>
<td>6%</td>
<td>6%</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>Diazepam (1E-10 - 9E-05 M)</td>
<td>0%</td>
<td>1%</td>
<td>1%</td>
<td>4%</td>
<td>8%</td>
<td>9%</td>
<td>6%</td>
<td>4%</td>
<td>6%</td>
</tr>
<tr>
<td>Chlorpromazine (1E-9 - 0.9E-03 M)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>2%</td>
<td>13%</td>
<td>12%</td>
<td>5%</td>
</tr>
<tr>
<td>MK801 (1E-10 - 5E-05 M)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>4%</td>
<td>10%</td>
<td>11%</td>
<td>5%</td>
</tr>
<tr>
<td>Thiopental (1E-8 - 2E-05 M)</td>
<td>3%</td>
<td>3%</td>
<td>2%</td>
<td>5%</td>
<td>7%</td>
<td>8%</td>
<td>2%</td>
<td>1%</td>
<td>5%</td>
</tr>
<tr>
<td>Memantine (1E-14 - 1E-04 M)</td>
<td>0%</td>
<td>1%</td>
<td>0%</td>
<td>2%</td>
<td>2%</td>
<td>6%</td>
<td>7%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Valproate (1E-07 - 2E-02 M)</td>
<td>1%</td>
<td>2%</td>
<td>2%</td>
<td>5%</td>
<td>3%</td>
<td>1%</td>
<td>2%</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Amitriptyline (1E-12 - 1E-03 M)</td>
<td>5%</td>
<td>3%</td>
<td>5%</td>
<td>5%</td>
<td>3%</td>
<td>0%</td>
<td>4%</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Retigabine (1E-10 - 1E-04 M)</td>
<td>7%</td>
<td>5%</td>
<td>6%</td>
<td>6%</td>
<td>4%</td>
<td>2%</td>
<td>0%</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Clonazepam (1E-11 - 1E-04 M)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>4%</td>
<td>6%</td>
<td>3%</td>
<td>3%</td>
</tr>
<tr>
<td>Baclofen</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>sum</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>
Figure 11

(A) The graph shows the beam walk (Foot slips/Falls) for different concentrations of PEG400 (10, 30, 100 mg/kg). The data points are represented by black circles for Slips, white squares for Falls, and white circles for MEST. The error bars indicate the standard deviation.

(B) The graph depicts the maximal electroshock threshold for 10% HPbc (0.3, 1, 3 mg/kg) and Diazepam (0.3, 1, 3 mg/kg). The data points are represented by black circles for Slips, white squares for Falls, and white circles for MEST. The error bars show the standard deviation.